



which

ipd

ay to see

Th ~~ed~~ b a ~~a~~

Statement of Assets and Liabilities

December 31, 2023 (continued)	AC VP	AC VP	AC VP	AC VP	AC VP
	Income	Income	Market Value	Unrealized	Value
	Category I	Category II	Category II	Category II	Category I
Assets					
U.S. Government Securities	\$.	\$.	\$.	\$.	\$.
U.S. Corporate Bonds					
U.S. International Bonds					
U.S. Equity					
U.S. International Equity					
Real Estate					
Commodities					
Other					
Total Assets	\$.	\$.	\$.	\$.	\$.
Liabilities					
Accounts Payable					
Accrued Expenses					
Other					
Total Liabilities	\$.	\$.	\$.	\$.	\$.

December 31, 2023 (continued)	AC VP	Bac R c,	Bac R c,	BNY M	Ca / VP
	Value	Adri SMID Ca, VI,	G ha A. c,	S J S E,	EAFE I - I d ,
	Category II	Category III	Category III	Category I	Category F
Assets					
U.S. Government Securities	\$.	\$.	\$.	\$.	\$.
U.S. Corporate Bonds					
U.S. International Bonds					
U.S. Equity					
U.S. International Equity					
Real Estate					
Commodities					
Other					
Total Assets	\$.	\$.	\$.	\$.	\$.
Liabilities					
Accounts Payable					
Accrued Expenses					
Other					
Total Liabilities	\$.	\$.	\$.	\$.	\$.

Statement of Assets and Liabilities

	Contract Value 100	Contract Value 2000	Contract Value SRI Based	Contract Value SRI Based	Contract Value SRI Based
Assets					
Investment in Variable Annuity Contracts	\$ 100.00	\$ 2000.00	\$ 100.00	\$ 100.00	\$ 100.00
Investment in Fixed Income Securities					
Investment in Equity Securities					
Investment in Real Estate Securities					
Investment in Alternative Investments					
Investment in Cash and Cash Equivalents					
Investment in Other Assets					
Liabilities					
Contractholder's Account					
Investment Management Fees					
Administrative Expenses					
Other Liabilities					
Total	\$ 100.00	\$ 2000.00	\$ 100.00	\$ 100.00	\$ 100.00

	Contract Value 2	Contract Value 3	Contract Value SRI Based	Contract Value SRI Based	Contract Value SRI Based
Assets					
Investment in Variable Annuity Contracts	\$ 2.00	\$ 3.00	\$ 2.00	\$ 2.00	\$ 2.00
Investment in Fixed Income Securities					
Investment in Equity Securities					
Investment in Real Estate Securities					
Investment in Alternative Investments					
Investment in Cash and Cash Equivalents					
Investment in Other Assets					
Liabilities					
Contractholder's Account					
Investment Management Fees					
Administrative Expenses					
Other Liabilities					
Total	\$ 2.00	\$ 3.00	\$ 2.00	\$ 2.00	\$ 2.00

Statement of Assets and Liabilities

December 31, 2023 (continued)	C_VP Direct	C_VP Direct	C_VP Direct	C_VPE Mutual	C_VP Mutual
	C 3	C 2	C 3	C 2	C 2
Assets					
Investments in Variable Annuity Contracts	\$ 100.00	\$ 100.00	\$ 100.00	\$ 100.00	\$ 100.00
Investments in Fixed Annuity Contracts					
Investments in Other Contracts					
Investments in Other Assets					
Total Assets	\$ 100.00	\$ 100.00	\$ 100.00	\$ 100.00	\$ 100.00
Liabilities					
Liabilities to Policyholders					
Liabilities to Other Parties					
Liabilities to Other Assets					
Total Liabilities	\$ 100.00	\$ 100.00	\$ 100.00	\$ 100.00	\$ 100.00

December 31, 2023 (continued)	C_VP EM	C_VPG ba Safeco	C_VPG ba Safeco	C_VPG M M	C_VPG M M
	C 3	C 2	C 3	C 2	C 3
Assets					
Investments in Variable Annuity Contracts	\$ 100.00	\$ 100.00	\$ 100.00	\$ 100.00	\$ 100.00
Investments in Fixed Annuity Contracts					
Investments in Other Contracts					
Investments in Other Assets					
Total Assets	\$ 100.00	\$ 100.00	\$ 100.00	\$ 100.00	\$ 100.00
Liabilities					
Liabilities to Policyholders					
Liabilities to Other Parties					
Liabilities to Other Assets					
Total Liabilities	\$ 100.00	\$ 100.00	\$ 100.00	\$ 100.00	\$ 100.00

Statement of Assets and Liabilities

December 31, 2023 (continued)

	C_YP HYB C 2	C_YP HYB C 3	C_YP ICB C 2	C_YP ICB C 3	C_YP IB C 2
--	--------------------	--------------------	--------------------	--------------------	-------------------

Assets

U.S. Treasury Bills	\$ 1.1	\$ 1.1	\$ 1.1	\$ 1.1	\$ 1.1
---------------------	--------	--------	--------	--------	--------

Liabilities

Accounts Payable

Accrued Expenses

Deferred Income

Other Liabilities

Statement of Assets and Liabilities

December 31, 2023 (continued)

	C_VPS_c M d'Ca' Va, C 3	C_VPS_c S Ca' Va, C 2	C_VPS_c S Ca' Va, C 3	C_VPS_c Gh T c', C 2	C_VP S Ca' Va, C 2
--	-------------------------------	-----------------------------	-----------------------------	----------------------------	--------------------------

Assets

Current Assets	\$. . .	\$. . .	\$. . .	\$. . .	\$. . .
----------------	----------	----------	----------	----------	----------

Liabilities

Current Liabilities

Long-Term Liabilities

Statement of Assets and Liabilities

	CTIVP V S ca E Va, C 3	CTIVP W d M d Ca, G C 2	D_ Ir VIP A S a C II	D_ VIP J c, S C	D_ VIP I, S C
Assets					
Current Assets	\$ 100	\$ 0	\$ 0	\$ 0	\$ 0
Investments	0	0	0	0	0
Real Estate	0	0	0	0	0
Other Assets	0	0	0	0	0
Total Assets	\$ 100	\$ 0	\$ 0	\$ 0	\$ 0
Liabilities					
Current Liabilities	0	0	0	0	0
Long-Term Liabilities	0	0	0	0	0
Total Liabilities	\$ 0	\$ 0	\$ 0	\$ 0	\$ 0

	DWS A A A c, VIP, C B	EV VT E a, i -Ra l c, I C	F d VIP C a d, S C 2	F d VIP E M S C 2	F d VIP E i, S C 2
Assets					
Current Assets	\$ 100	\$ 0	\$ 0	\$ 0	\$ 0
Investments	0	0	0	0	0
Real Estate	0	0	0	0	0
Other Assets	0	0	0	0	0
Total Assets	\$ 100	\$ 0	\$ 0	\$ 0	\$ 0
Liabilities					
Current Liabilities	0	0	0	0	0
Long-Term Liabilities	0	0	0	0	0
Total Liabilities	\$ 0	\$ 0	\$ 0	\$ 0	\$ 0

Statement of Assets and Liabilities

December 31, 2023 (continued)	Fiduciary	Fiduciary	Fiduciary	Fiduciary	Fiduciary
	General	General	General	General	General
Assets					
Current Assets	\$ 1.1	\$.1	\$.1	\$ 1.1	\$.1
Investments			1.		
Real Estate			1.		
Other Assets	1.	1.		11.	1.
Total Assets	\$ 1.1	\$.1	\$.1	\$ 1.1	\$.1
Liabilities					
Accounts Payable	.1				
Other Liabilities	1.			1.	
Total Liabilities	\$ 1.1	\$.1	\$.1	\$ 1.1	\$.1

December 31, 2023 (continued)	Fiduciary	Fiduciary	Fiduciary	Fiduciary	Fiduciary
	Management	Management	Management	Management	Management
Assets					
Current Assets	\$.1	\$.1	\$.1	\$.1	\$.1
Investments		1.1		1.	
Real Estate					
Other Assets					
Total Assets	\$.1	\$ 1.1	\$.1	\$ 1.	\$.1
Liabilities					
Accounts Payable					
Other Liabilities					
Total Liabilities					

S a e e d f A e a d L i a b i l i e

D c b 31, 2023 (c 7 d)	F a G h a R a E C 2	F a I c, C 2	F a I c, C 4	F a M 7 a G h D C 4	F a M 7 a S a C 2
A					
	\$. .	\$. .	\$. /	\$. /	\$. / .
		/	/		
		/ /			/ /
L a b					
			/		/
					/
		/	/		/
	/ /	/ /			/ /
			/		
	\$. .	\$. .	\$. /	\$. /	\$. / .
			/ /	/	/ /
	\$. .	\$. / .	\$. .	\$. .	\$ / . /

D c b 31, 2023 (c 7 d)	F a S C a i V a , C 2	F a S C a i V a , C 4	GS VIT M d C a i V a , I	GS VIT M 7 - S a i A , A d /	GS VIT M 7 - S a i A , S
A					
	\$. / . / /	\$. / .	\$. .	\$. /	\$. /
		/			
	/ .	/ .	/		
L a b					
			/	/	
		/			
			/ /		/
	\$. / . / /	\$. / .	\$. .	\$. /	\$. /
	\$ / . .	\$ / . /	\$. .	\$. .	\$. .



S a e e s f A e a d Liabi e

[Redacted]

[Redacted]

[Redacted]

Statement of Assets and Liabilities

December 31, 2023 (continued)	Liquid Assets	Liquid Assets	LVIP JPM	MFS	MFS
	Balances	Share	US Equity	Global Equity	Income
Assets					
Investments	\$ 1.0	\$.	\$.	\$.1	\$.
Other Assets				.11	
Liabilities					
Accounts Payable					
Other Liabilities					
Total Liabilities	\$ 1.0	\$.	\$.	\$.1	\$.
Net Assets	\$.	\$ 1.0	\$.1	\$.	\$.1

December 31, 2023 (continued)	MFS	MFS	MFS	MFS	MS
	Income	Income	Income	Income	Income
Assets					
Investments	\$.1	\$.1	\$.	\$.	\$.
Other Assets		.11		.1	
Liabilities					
Accounts Payable					
Other Liabilities					
Total Liabilities	\$.1	\$.1	\$.	\$.	\$.
Net Assets	\$.	\$.	\$.	\$.	\$.

S a e e s f A e a d L i a b i l i e

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

Statement of Assets and Liabilities

December 31, 2023 (continued)	P/V	P/V	P/V	P/V	R/C
	Market Value, CIB	Share, CIB	Share, CIA	Share, CIB	Market Value, CIA
Assets					
Investments	\$ 1.00	\$.00	\$ 1.00	\$.00	\$.00
Accounts receivable					
Prepaid expenses					
Other assets					
Liabilities					
Accounts payable					
Accrued expenses					
Other liabilities					
Total	\$ 1.00	\$.00	\$ 1.00	\$.00	\$.00

December 31, 2023 (continued)	T/G	T/V	Va Ec	VP	VP
	Balance, C2	Balance, C3	Balance, C3	Balance, C2	Balance, C4
Assets					
Investments	\$.00	\$.00	\$ 1.00	\$ 1.00	\$.00
Accounts receivable					
Prepaid expenses					
Other assets					
Liabilities					
Accounts payable					
Accrued expenses					
Other liabilities					
Total	\$.00	\$.00	\$ 1.00	\$ 1.00	\$.00

S a e e s f A e a d L i a b i l i e

VP
C

D c b 31, 2023 (c r d)

[Redacted]

[Redacted]

[Redacted]

[Redacted]

S a e e s f A e a d Liabi e

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

S a e e x f O e a i x

Y a d d D c b 31, 2023 (c 7 d)	C_YP I B d, C 3	C_YP M Ca' G C 2	C_YP M Ca' G C 3	C_YP M Ca' d C 2	C_YP M Ca' d C 3
I / c					
	\$. /	\$	\$	\$ 1.1	\$
		(.)	(.)	(1.1)	(.)
R a d a d 7 a d a (
	1.1	.	.	1.1	.
	.	1.	.	1.	1.1
	(.)	1.1	.	.	.

[Redacted]

[Redacted]

[Redacted]

[Redacted]

S a e e x f O e a i x

Y a d d D c b 31, 2023 (c 7 d)	C_VPS_c M d C a i Va, C 3	C_VPS_c S C a i Va, C 2	C_VPS_c S C a i Va, C 3	C_VPS_ G b T c i, C 2	C_VP S C a i Va, C 2
I / c					
	\$	\$	\$	\$	\$
		.11			
	((.11	(((
R a d a d 7 a d i a					
			.1		
		.11			
	1.	1.	.11		
				1.1	
				.1	
				.1	
	(.11	(.11	(.11	(.11	(.11

[Redacted line]

[Redacted line]

[Redacted line]

[Redacted line]

[Redacted line]

[Redacted line]

[Redacted line]

[Redacted line]

[Redacted line]

[Redacted line]

[Redacted line]

[Redacted line]

S a e e r f O e a i r

Y a d d D c b 31, 2023 (c r d)	CTIVP	CTIVP	CTIVP	CTIVP TCW	CTIVP
	P B r C u G C 1	P B r C u G C 2	T R P c C a Va, C 2	C P r B d, C 2	V S ca E a Va, C 2
I / c					
	\$.	\$.	\$.	\$.	\$.
	(.	(.	(.	. //	(.
R a d a r a d i a					
	. / /
	. /
	. /	.	. /	(.	. /
	. / . /	.	. /	. /	.
	. / /
	\$.	\$.	\$.	\$. /	\$.

Y a d d D c b 31, 2023 (c r d)	CTIVP	CTIVP	D_ Ir	D_ VIP	D_ VIP
	V S ca E a Va, C 3	W d M d Ca, G C 2	VIP A S a r, C II	D_ VIP J c, S V C	D_ VIP I, S V C
I / c					
	\$. /	\$. /	\$.	\$.	\$. /
	(. /	(. /	.	. //	(.
R a d a r a d i a					
	.	. /	. /	. /	. /
	.	. /	(.	.	. /
	.	. /	.	. /	.
	. /
	\$. /	\$.	\$.	\$. /	\$.

Y a d d D c b 31, 2023 (c r d)	DWS	EV VT	F d VIP	F d VIP	F d VIP
	A A A c, VIP, C B	E a r- Ra l c, I C	C a r d, S V C 2	E M S V C 2	E r, S V C 2
I / c					
	\$. /	\$. /	\$.	\$. /	\$. /
	.	. /	(.	.	.
R a d a r a d i a					
	. /	. /	. /	. /	.
	(. /	(. /	. /	.	. /
	. /	.	.	.	(. /
	(.	.	.	.	(. /
	\$.	\$.	\$.	\$.	\$ (.

S a e e . f O e a i .

Y a d d D c b 31, 2023 (c 7 d)

F d V I P F d V I P F d V I P F d V I P F d V I P
G & I c, G & I c, G Q u, I - C a i A m, I / S,
S v C S v C 2 S v C 2 S v C 2 S v C 2

[REDACTED]

\$. \$. \$ \$ \$.

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

S a e e a f O e a i a

Y a d d D c b 31, 2023 (c 7 d)

F a S
C a i V a ,
C 2

F a S
C a i V a ,
C 4

GS VIT
M d C a i V a ,
I

GS VIT
M 7 - S a i A ,
A d r

GS VIT
M 7 - S a i A ,
S v

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

S a e e r f O e a i r

Y a d d D c b 31, 2023 (c 7 d)	I r e VI D M d C a i G S II	I r e VI D r D r d S I	I r e VI D r D r d S II	I r e VI E Q V I - E S II	I r e VI G b a S II
I r e c					
	\$.	\$.	\$.	\$.	\$.
	(.)			(.)	(.)
R a d a d 7 a d i a					
				. /	. /
	. /				. /
	(.)			(.)	(. /
	. /	(.)	(.)		. /
	. /		. /		. / . /
	\$.	\$.	\$.	\$ / .	\$. / .

Y a d d D c b 31, 2023 (c 7 d)	I r e VI G b S a i c S II	I r e VI H S II	I r e VI M a S S II	I r e VI M S S C a i S II	I r e VI T c S I
I r e c					
	\$.	\$.	\$.	\$.	\$.
				. /	
	(.)	(.)	(.)	(.)	(.)
R a d a d 7 a d i a					
	. /			. /	. / . /
	. /	. /	. /	. /	
	(.)	(.)	(.)		(.)
				. /	. /
	. /			. / . /	
	\$. /	\$.	\$.	\$ / .	\$.

Y a d d D c b 31, 2023 (c 7 d)	I r e VI T c S II	J a H d V I T B a S V	J a H d V I T E S V	J a H d V I T E B d S V	J a H d V I T F S V
I r e c					
	\$.	\$.	\$.	\$.	\$.
				. /	
	(.)	. /	(. /	. /	(. /
R a d a d 7 a d i a					
		. /	. /		. /
			. /	(.)	
	. /		. /		
		. /			
	\$. / .	\$.	\$.	\$ / .	\$.

Sae ea fO eai

Y a d d D c b 31, 2023 (c 7 d)

	Ja 7 H d VIT Gb T c I S	Ja 7 H d VIT Or S	Ja 7 H d VIT R S	La a d R E M S	La a d R G ba D MA, S
--	-------------------------------	----------------------------	---------------------------	----------------------	-----------------------------

I

	\$	\$	\$	\$	\$
	/	.	/ /		
	(/	.	(/ /	/	(

R a d a d 7 a d i a

				/	
	/	.	/ /	/	
	/ /	/	.	(//
	/	.	/ /	/	/ x

[Redacted Section]

[Redacted Section]

[Redacted Section]

[Redacted Section]

[Redacted Section]

S a e e x f O e a i x

Y a d d D c b 31, 2023 (c 7 d)	MS VIF G ba R a E C II	NB AMT I _ E C S	NB AMT S 7 E C S	NB AMT US E J d PWS a, C S	PIMCO VIT A. A Ad r C
I / c					
	\$.	\$.	\$ /	\$.	\$ //.
					/
		(.	(.	(.	
R a d a d 7 a d i a (
	(. /	(.		(.	(/
	/		//		
			//	/	
	\$.	\$.	\$.	\$ /	\$.

Y a d d D c b 31, 2023 (c 7 d)	PIMCO VIT G b Ma A c Ad r C	PIMCO VIT T R 7, Ad r C	P 7 VT G ba H \ Ca, C IB	P 7 VT I _ E C IB	P 7 VT I _ Va, C IB
I / c					
	\$.	\$.	\$.	\$.	\$
	//	/ /			
	/	/.	(. /	(.	
R a d a d 7 a d i a (
	/		/	/.	/
			/	/	/
	(. /	(/		/	
	/		/		
		/			
	\$.	\$.	\$ /.	\$ /.	\$. /

Y a d d D c b 31, 2023 (c 7 d)	P 7 VT I Ca, Va, C IB	P 7 VT S 7 7, C IB	P 7 VT S 7 ad C IA	P 7 VT S 7 ad C IB	R c M c - Ca, I /
I / c					
	\$.	\$.	\$ //	\$.	\$
				/	
		(.	(.	(.	(.
R a d a d 7 a d i a (
	/	/	// /	/	
	/				
	(.		/.		(.
			/.		
	/.		/	/	
	\$.	\$.	\$. /	\$.	\$. /

S a e e x f O e a i x

Y a d d D c b 31, 2023 (c 7 d)	V P M d, A i, C 2	V P M d, A i, C 4	V P M d, C C 2	V P M d, C C 4	V P P C B d, C 2
I / c					
	\$	\$	\$	\$	\$
	(.)	(.)	(.)	(.)	(.)
R a d a d 7 a d i a					
	
		
			(.)
			
			
	\$	\$	\$	\$	\$

Y a d d D c b 31, 2023 (c 7 d)	V P P C E, C 2	V P P C E, C 3	V P P I C E, C 2	V P P I G, C 2	V P P I Va, C 2
I / c					
	\$	\$	\$	\$	\$
	(.)	(.)		(.)	
R a d a d 7 a d i a					
				
	(.)	(.)	(.)
		
	
	\$	\$	\$	\$	\$

Y a d d D c b 31, 2023 (c 7 d)	V P P S C a i G, C 2	V P P S C a i Va, C 2	V P P S C a i Va, C 3	V P U S E C G, C 2	V P U S E G, C 2
I / c					
	\$	\$	\$	\$	\$
	(.)	(.)	(.)	(.)	(.)
R a d a d 7 a d i a					

	
		
				
	\$	\$	\$	\$	\$

Y a d d D c b 31, 2023 (c 7 d)

S a e e f Change in Ne A e

AB VPS D AB VPS AB VPS
A A c
G B I Va,
G B

Y a d d D c b 31, 2023



Statement of Change in Net Assets

Year ended December 31, 2023 (continued)	ALPSA Variable Annuity Contract	ALPSA Variable Annuity Contract	ALPSA Variable Annuity Contract	ALPSA Variable Annuity Contract	ALPSA Variable Annuity Contract
	Investment Income	Expenses	Other	Shareholder Contributions	Net Change
Operating					
Interest income	\$.	\$.	\$.	\$.	\$.
Dividend income	.	(.)	. /	(. /)	.
Capital gains	. /	.	.	. /	.
Net investment income	. /	. /	.	. /	. /
Contract Administration					
Contract acquisition costs	.	(. /)	.	.	(. /)
Contract maintenance costs	.	(. /)	.	.	(. /)
Contract termination costs	(. /)	(. /)	(. /)	(. /)	(. /)
Net contract administration costs	(. /)	(. /)	(. /)	(. /)	(. /)
Net investment income	. /	(. /)	(. /)	(. /)	(. /)
Net contract administration costs	. /	. /	. /	. /	. /
Accumulated					
Net investment income /	.
Net contract administration costs	. /	(. /)	(. /)	(. /)	(. /)
Net change	. /	(. /)	(. /)	(. /)	(. /)

Statement of Change in Net Assets

Year Ended December 31, 2023 (continued)	AC VP Value, C II	Bac R c, Ad/ SMID Ca, VI, C III	Bac R c, G ha A, C III	BNY M S 7 USE S r	Ca / VP EAFE I - I d C F
Operating					
Net investment income	\$.	\$. /	\$ /.	\$ (\$. /
Net investment expenses	(.	(.	(.	((.
Net investment income	(. /	(.	(.	((. /
Net investment income	(.	(.	(. /	((. /
Capital Gains					
Net capital gains	(. /	(.	(. /	(/	(.
Net capital gains	(. /	(.	(.	(/	(.
Net capital gains	(/ . /	(.	(. /	(/	(.
Net capital gains	(. /	(.	(.	((.
Net investment income	(/ .	(.	(.	((. /
Net investment income	(.	(.	(.	(/	(.
Net investment income	\$. . /	\$. /	\$. .	\$.	\$.
Accretion					
Net accretion	(. /	(. /	(.	((. /
Net accretion	(. /	(. /	(.	((. /
Net accretion	(. /	(. /	(.	((. /
Net accretion	(. /	(. /	(.	((. /

S a e e . f C h a n g e i n N e A e

Y a d d D c b 31, 2023 (c . 7 d)	C_YP Ba, C 2	C_YP Ba, C 3	C_YP S a f, C 2	C_YP C a a C 2	C_YP D a d C 2
----------------------------------	--------------------	--------------------	-----------------------	----------------------	----------------------



Statement of Change in Net Assets

Year ended December 31, 2023 (continued)	C_VP E M C 3	C_VP G ha S a i c l c, C 2	C_VP G ha S a i c l c, C 3	C_VP G r, M M, C 2	C_VP G r, M M, C 3
	Operating				
Operating income	\$ ()	\$ ()	\$ ()	\$.1	\$.1
Operating expenses	(.1	(.1	(.1		.1
Operating loss			.1	()	()
Operating gain		.1	.11	.1	.1
Capital					
Capital contributions				.11	.1
Capital distributions				()	()
Capital gain	()	()	()	()	()
Capital loss	()	()	(.1	(.1 .1	()
Capital change	(.11	()	()	(.1	()
Capital at end of year	()		()	.11	()
Capital at beginning of year		.1			.1
Capital at end of year	\$. .	\$. .	\$. .	\$.1	\$.1
Accumulated depreciation					

Statement of Change in Net Assets

Year ended December 31, 2023 (continued)	C_YP H Y_d B d, C 2	C_YP H Y_d B d, C 3	C_YP I c O i i, C 2	C_YP I c O i i, C 3	C_YP I B d, C 2
	Operating				
Revenue	\$.	\$.	\$.	\$.	\$.
Expenses	(. /	(/	(.	(.	(. /
Change in net assets	/	.	/	/	.
Net assets at beginning of year	.	.	/	.	.

Capital					
Contributions	.	/	/	/	.
Reserves	(. /	.	(.	(.	.
Retained earnings	(.	((.	(.	.

Statement of Change in Net Assets

Year ended December 31, 2023 (continued)	Cash, Cash Equivalents, and Short-Term Investments	Investments	Real Estate	Other Assets	Total
Operating Activities					
Net income	\$ 1,000	\$ (500)	\$ (500)	\$ (1,000)	\$ (500)
Depreciation and amortization	(1,000)	1,000			
Gain on sale of investments	1,000	(1,000)			
Change in accounts payable			1,000		1,000
Change in other liabilities				1,000	1,000
Net change in operating activities	\$ 1,000	\$ (500)	\$ (500)	\$ (1,000)	\$ (500)
Investing Activities					
Acquisition of investments		1,000			1,000
Disposal of investments	1,000	(1,000)			
Acquisition of real estate			(1,000)		(1,000)
Disposal of real estate	(1,000)		1,000		
Change in other assets	(1,000)				(1,000)
Net change in investing activities	\$ (1,000)	\$ (1,000)	\$ (1,000)	\$ (1,000)	\$ (4,000)
Financing Activities					
Proceeds from operations	1,000	1,000	1,000	1,000	4,000
Proceeds from investments	1,000	1,000			2,000
Proceeds from real estate	(1,000)	(1,000)			(2,000)
Net change in financing activities	\$ 1,000	\$ 1,000	\$ 1,000	\$ 1,000	\$ 4,000
Net change in total assets	\$ 1,000	\$ (500)	\$ (500)	\$ (1,000)	\$ (500)
Assets at beginning of year	\$ 10,000	\$ 10,000	\$ 10,000	\$ 10,000	\$ 40,000
Assets at end of year	\$ 11,000	\$ 9,500	\$ 9,500	\$ 9,000	\$ 39,000



Statement of Change in Net Assets

Year ended December 31, 2023 (continued)	C_YPL d L G / D a C, C B d, C 2 C 2	C_YPL L G / C B d, C 2	C_YPL Or C 2	C_YPL Or C 3	C_YPL S_c C a E C 2
	Operating				
Net investment income	\$ 1.1	\$.	\$.	\$.	\$ (
Net investment expenses	(.1)	(.1)	(.1)	(.1)	.1
Net investment income	.11
Net investment expenses	.	.1	.	.1	.1
Capital Gains					
Net capital gains	.1	.	(.1)	.	.1
Net capital losses	(.1)	(.1)	(.1)	(.1)	.
Net capital gains	(.1)	(.1)	(.1)	(.1)	(.1)
Net capital losses	(.1)	(.1)	(.1)	(.1)	(.1)
Net capital gains	(.1)	.1	.1	(.1)	.1
Net capital losses	.	.	.1	.1	.
Net capital gains	\$.1	\$.1	\$.	\$.	\$.1
Accretion					
Net accretion
Net accretion	.1
Net accretion	(.1)	(.1)	(.1)	(.1)	.
Net accretion	.	.1	.1	.	.

S a e e . f C h a n g e i n N e A e

C_ Y P S_ c C_ 3 P S_ c
M d C a i V a , S C a i V a ,
C 3

Y a d d D c b 31, 2023 (c 7 d)



Statement of Change in Net Assets

Year ended December 31, 2023 (continued)

	CTIVP V S ca E Va, C 3	CTIVP W d M d Ca, G C 2	D_ Ir VIP A S a I, C II	D_ VIP J c, S v C	D_ VIP I, S v C
--	---------------------------------	----------------------------------	----------------------------------	-------------------------	-----------------------

Operating income	\$ ()	\$ ()	\$.	\$.	\$ ()
Operating expenses					
Net operating income					
Other income					
Other expenses					
Net change in net assets					
Net assets at beginning of year					
Net assets at end of year					

(\$ / . \$ / . \$ / . \$ / . \$ / .)

Statement of Change in Net Assets

Year ended December 31, 2023 (continued)	DWS	EVT	FdVIP	FdVIP	FdVIP
	Assets, C/B	Equity, I/C	Contributions, S/C 2	Expenses, S/C 2	Expenses, S/C 2

Operating

Operating income	\$.	\$. / /	\$ (. /	\$.	\$.
Operating expenses	(. /	(. /	. /		/

Investment

Investment income					
Investment expenses					
Net investment income					
Net change in net assets					

Other

Other income					
Other expenses					
Net other income					

Statement of Change in Net Assets

Year ended December 31, 2023 (continued)

	Fiduciary Gross Income, Schedule C	Fiduciary Gross Income, Schedule C-2	Fiduciary Gross Income, Schedule C-2	Fiduciary Income, Capital Gains, Schedule C-2	Fiduciary Income, Capital Gains, Schedule C-2
Operating					
Operating income	\$ 1,100	\$ 1,100	\$ (1,100)	\$ (1,100)	\$ -
Operating expenses	(1,100)	(1,100)	(1,100)	(1,100)	(1,100)
Operating loss	-	-	-	-	-
Operating gain	1,100	1,100	1,100	1,100	1,100

	Fiduciary Gross Income, Schedule C	Fiduciary Gross Income, Schedule C-2	Fiduciary Gross Income, Schedule C-2	Fiduciary Income, Capital Gains, Schedule C-2	Fiduciary Income, Capital Gains, Schedule C-2
Capital					
Capital gain	-	1,100	1,100	-	-
Capital loss	-	(1,100)	(1,100)	(1,100)	(1,100)
Capital gain	-	(1,100)	(1,100)	(1,100)	(1,100)
Capital loss	(1,100)	(1,100)	(1,100)	(1,100)	(1,100)
Capital gain	(1,100)	(1,100)	(1,100)	(1,100)	(1,100)
Capital loss	(1,100)	(1,100)	(1,100)	(1,100)	(1,100)



Statement of Change in Net Assets

Year ended December 31, 2023 (continued)	Fiduciary Modular SVC	Fiduciary Modular SVC 2	Fiduciary Orphan SVC	Fiduciary Orphan SVC 2	Fiduciary Special SVC 2
Operating					
Operating income	\$ ()	\$ ()	\$ /	\$ ()	\$ ()
Operating expenses	/	(/)			()
Operating loss	/				
Operating gain					/
Operating loss	/	/			
Capital					
Capital gains		/		/	/
Capital losses		/	/		()
Capital income		(/)			()
Capital expenses					/
Capital gain	(/)	()	()	()	()
Capital loss	()	()	(/)	()	()
Capital income	()	(/)	(/)	(/)	()
Capital expenses		/	/	/	/
Capital gain	\$.	\$.	\$.	\$. /	\$.
Accrual					
Accrual income	/	/			
Accrual expenses					/
Accrual gain	()	()	()	()	(/)
Accrual loss	/	/	/		/

S a e e f C h a n g e i n A e



Statement of Change in Net Assets

Year ended December 31, 2023 (continued)	Fair Value, Class 2	Fair Value, Class 4	GS VIT Modified Value, 1	GS VIT Modified Value, 5A	GS VIT Modified Value, 5A
Operating Activities					
Net income	\$ 1.1	\$.	\$ 1.	\$.	\$.
Depreciation and amortization	(.)	(.)	(.)	(.)	(.)
Provision for doubtful accounts	(.)	(.)	(.)	(.)	(.)
Gain on sale of equipment	1.	(.)	(.)	(.)	(.)
Change in accounts payable	.1	(.)	.1	(.)	.1
Change in accrued liabilities	(.)	(.)	(.)	(.)	(.)
Change in other assets	(.)	(.)	(.)	(.)	(.)
Change in other liabilities	(.)	(.)	(.)	(.)	(.)
Change in other net assets	(.)	(.)	(.)	(.)	(.)
Change in net assets	\$ 1.1	\$.	\$ 1.	\$.	\$.
Investing Activities					
Capital expenditures	(.)	(.)	(.)	(.)	(.)
Proceeds from sale of equipment	1.	(.)	(.)	(.)	(.)
Proceeds from sale of investments	(.)	(.)	(.)	(.)	(.)
Change in other assets	(.)	(.)	(.)	(.)	(.)
Change in other liabilities	(.)	(.)	(.)	(.)	(.)
Change in other net assets	(.)	(.)	(.)	(.)	(.)
Change in net assets	\$ 1.1	\$.	\$ 1.	\$.	\$.
Financing Activities					
Proceeds from sale of investments	(.)	(.)	(.)	(.)	(.)
Change in other assets	(.)	(.)	(.)	(.)	(.)
Change in other liabilities	(.)	(.)	(.)	(.)	(.)
Change in net assets	(.)	(.)	(.)	(.)	(.)

Statement of Change in Net Assets

Year ended December 31, 2023 (continued)	GS VIT	GS VIT	GS VIT U.S.	GS VIT VI	GS VIT VI
	Subchapter S Corporation	Subchapter S Corporation	Subchapter S Corporation	Subchapter S Corporation	Subchapter S Corporation
Operating Activities					
Net income	\$ 100	\$ 100	\$ (100)	\$ (100)	\$ (100)
Depreciation and amortization	(100)	(100)	(100)	(100)	(100)
Change in accounts receivable	100	100	100	100	100
Change in accounts payable	100	100	100	100	100
Change in other assets and liabilities	100	100	100	100	100
Net change in operating activities	100	100	(100)	(100)	(100)
Investing Activities					
Capital expenditures	(100)	(100)	(100)	(100)	(100)
Proceeds from sale of assets	100	100	100	100	100
Change in other assets and liabilities	(100)	(100)	(100)	(100)	(100)
Net change in investing activities	(100)	(100)	(100)	(100)	(100)
Financing Activities					
Proceeds from issuance of common stock	100	100	100	100	100
Change in other assets and liabilities	(100)	(100)	(100)	(100)	(100)
Net change in financing activities	100	100	100	100	100
Net change in net assets	100	100	(100)	(100)	(100)
Net assets at beginning of year	100	100	100	100	100
Net assets at end of year	200	200	100	100	100

Statement of Change in Net Assets

Year ended December 31, 2023 (continued)	Global, S II		Hedge, S II		Master, S II		Master, S II	
Operating Income								
Operating income	\$ ()	\$ ()	\$ ()	()	\$ ()	()	\$ ()	()
Operating expenses	()	()	()	()	()	()	()	()
Operating income								
Other Income								
Other income								
Other expenses								
Other income								
Net Income								
Net income								
Net expenses								
Net income								
Net Realized Gain								
Net realized gain								
Net realized loss								
Net realized gain								
Net Change in Net Assets								
Net change in net assets								
Net change in net liabilities								
Net change in net assets								

Global, Hedge, Master, Master, Net Realized Gain, Net Change in Net Assets, Net Change in Net Liabilities, Net Change in Net Assets

S a e e f C h a n g e i n A e

Ja 7 H d	Ja 7	Ja 7	La a d R	La a d R
VIT Gb T c\	H d	H d	E M	T c\ TJD M
I	VIT O	VIT R	S	
S	S	S	S	

Y a d d D c b 31, 2023 (c 7 d)

[Redacted]

[Redacted]

[Redacted]

[Redacted]

Statement of Change in Net Assets

Year ended December 31, 2023 (continued)	Local Assets USD, net of contract value	Local Assets USD, net of contract value	LVIP JPM US E- SVC (2)	MFS Global SVC	MFS Global SVC
Operating					
Operating income	\$.	\$.	\$ (\$ (\$ (
Operating expenses	((/	/	/
Operating loss	((/	/	/
Operating gain	/	/	/	/	/
Capital					
Capital gains	/	/	/	/	/
Capital losses	(((((
Capital income	(/)	(/)	(/)	(/)	(/)
Capital loss	(/)	(/)	(/)	(/)	(/)
Capital gain	/	/	/	/	/
Capital loss	/	/	/	/	/
Capital gain	\$ /	\$ /	\$ /	\$ /	\$ /
Accrual					
Accrual income	//	//	/	/	/
Accrual loss	(/)	(/)	(/)	(/)	(/)
Accrual gain	/	/	/	/	/
Accrual loss	(/)	(/)	(/)	(/)	(/)
Accrual gain	/	/	/	/	/

Statement of Change in Net Assets

Year ended December 31, 2023 (continued)

	Private Capital Value Added	Private Capital Value Added	Private Capital Value Added	Private Capital Value Added	Real Estate Investment
Operating	\$.	\$ (\$ (\$ (\$ (
Investment	((

Statement of Change in Net Assets

Year ended December 31, 2023 (continued)	Total Assets		Value of Investments		Value of Cash
	Beginning	Ending	Beginning	Ending	Ending
Operating Activities					
Net income	\$ ()	\$ ()	\$ ()	\$ ()	\$ ()
Change in cash	()	()	()	()	()
Change in investments	()	()	()	()	()
Change in other assets	()	()	()	()	()
Change in liabilities	()	()	()	()	()
Change in net assets	()	()	()	()	()
Investing Activities					
Change in cash	()	()	()	()	()
Change in investments	()	()	()	()	()
Change in other assets	()	()	()	()	()
Change in liabilities	()	()	()	()	()
Change in net assets	()	()	()	()	()
Financing Activities					
Change in cash	()	()	()	()	()
Change in investments	()	()	()	()	()
Change in other assets	()	()	()	()	()
Change in liabilities	()	()	()	()	()
Change in net assets	()	()	()	()	()

Statement of Change in Net Assets

Year ended December 31, 2023 (continued)	VP C 2	VP C 4	VP Ma R C 2	VP Ma R US, C 2	VP Ma V C 2
Operating	\$ ()	\$ ()	\$ ()	\$ ()	\$ ()
Investment					
Other					
Total					

S a e e l f C h a n g e i n N e A e

[Redacted]

[Redacted]

[Redacted]

[Redacted]

S a e e f Change i a Ne A e



Statement of Change in Net Assets

Year ended December 31, 2023 (continued)	VP US EM d, G C 2	Waif Ac	Waif I	WA Va G ba H Yd B d C II
Operating				
Revenue	\$ ()	\$ ()	\$ ()	\$ ()
Expenses	()	()	()	()
Net operating income	()	()	()	()
Capital				
Contributions	()	()	()	()
Revolving credit	()	()	()	()
Net capital	()	()	()	()
	\$ ()	\$ ()	\$ ()	\$ ()

Statement of Change in Net Assets

Year ended December 31, 2022	AB VPS Direct Assets, C/B	AB VPS Indirect Assets, C/B	AB VPS Mutual Funds, C/B	AB VPS Real Estate Assets, C/B	AB VPS Short-Term Assets, C/B
Operating Expenses					
Administrative expenses	\$.	\$.	\$ (.1)	\$.1	\$ (.
Investment expenses	(.1)	(.	.	.1	.
Other expenses	.1	.	.	.1	.1
	(.	(.1)	(.	(.	(.
	(.	(.	(.1)	(.	(.
Capital Gains					
Realized capital gains	.1	.1	.	.	.
Unrealized capital gains	.	(.1)	.11	(.1)	(.1)
Other capital gains	.	.1	.	.	.
	(.1)	(.1)	(.1)	(.1)	(.1)
	(.1)	(.1)	(.1)	(.1)	(.1)
	.	(.1)	.11	(.1)	(.1)
	.1	.	.1	.	.1
	\$.11	\$.1	\$.	\$.11	\$.
Accretion/Depletion					
Accretion/Depletion11	.1
	.1	.1	.1	.	.1
	(.1)	(.1)	(.1)	(.1)	(.1)
	.1	.1	.	.	.

Statement of Change in Net Assets

Year ended December 31, 2022 (continued)	Assets	Liabilities	Assets	Assets	ALPSA
	Current	Current	Current	Current	Current
Operating	\$ ()	\$ ()	\$ ()	\$ ()	\$ ()
Investment	()	()	()	()	()
Other	()	()	()	()	()
Net Change	()	()	()	()	()
Capital	()	()	()	()	()
Other	()	()	()	()	()
Net Change	()	()	()	()	()
Operating	()	()	()	()	()
Investment	()	()	()	()	()
Other	()	()	()	()	()
Net Change	()	()	()	()	()
Capital	()	()	()	()	()
Other	()	()	()	()	()
Net Change	()	()	()	()	()
Operating	()	()	()	()	()
Investment	()	()	()	()	()
Other	()	()	()	()	()
Net Change	()	()	()	()	()
Capital	()	()	()	()	()
Other	()	()	()	()	()
Net Change	()	()	()	()	()
Operating	()	()	()	()	()
Investment	()	()	()	()	()
Other	()	()	()	()	()
Net Change	()	()	()	()	()
Capital	()	()	()	()	()
Other	()	()	()	()	()
Net Change	()	()	()	()	()
Operating	()	()	()	()	()
Investment	()	()	()	()	()
Other	()	()	()	()	()
Net Change	()	()	()	()	()
Capital	()	()	()	()	()
Other	()	()	()	()	()
Net Change	()	()	()	()	()

Accumulated Depreciation

Operating	()	()	()	()	()
Investment	()	()	()	()	()
Other	()	()	()	()	()
Net Change	()	()	()	()	()
Capital	()	()	()	()	()
Other	()	()	()	()	()
Net Change	()	()	()	()	()

Statement of Change in Net Assets

Year ended December 31, 2022 (continued)	ACVP I, C I	ACVP I, C II	ACVP M d Ca, Va, C II	ACVP U a, C II	ACVP Va, C I
Operating					
Revenue	\$ 100	\$ 100	\$ 100	\$ (100)	\$ 100
Expenses	(100)	(100)	(100)	(100)	(100)
Change in net assets	(0)	(0)	(0)	(0)	(0)
Capital					
Contributions	100	100	100	100	100
Withdrawals	(100)	(100)	(100)	(100)	(100)
Change in net assets	0	0	0	0	0
Total					
Beginning balance	100	100	100	100	100
Change in net assets	(0)	(0)	(0)	(0)	(0)
Ending balance	100	100	100	100	100

Schedule of Change in Net Assets

Year ended December 31, 2022 (continued)	Carryover	2000	Carryover	Carryover	Carryover
	1001	1000	1001	1001	1001
	CF(2)	CF(2)	CF(2)	CF(2)	CF(2)
Operating					
Investment	\$ ()	\$ ()	\$ ()	\$ ()	\$ ()
Real Estate	()	()	()	()	()
Other	()	()	()	()	()

[Redacted section]

[Redacted section]

[Redacted section]

[Redacted section]

Statement of Change in Net Assets

Year ended December 31, 2022 (continued)	C_YP D C 3	C_YP D C 2	C_YP D C 3	C_YPE M C 2	C_YP E C 2
Operating Activities					
Net income	\$ (1.1)	\$ (1.1)	\$ (1.1)	\$ (1.1)	\$ (1.1)
Depreciation and amortization	0.1	0.1	0.1	0.1	0.1
Provision for doubtful accounts	0.1	0.1	0.1	0.1	0.1
Gain on sale of equipment	(0.1)	(0.1)	(0.1)	(0.1)	(0.1)
Change in accounts receivable	0.1	0.1	0.1	0.1	0.1
Change in accounts payable	(0.1)	(0.1)	(0.1)	(0.1)	(0.1)
Change in other assets and liabilities	0.1	0.1	0.1	0.1	0.1
Net change in operating activities	0.1	0.1	0.1	0.1	0.1
Investing Activities					
Capital expenditures	(0.1)	(0.1)	(0.1)	(0.1)	(0.1)
Proceeds from sale of equipment	0.1	0.1	0.1	0.1	0.1
Proceeds from sale of investments	0.1	0.1	0.1	0.1	0.1
Change in other assets and liabilities	0.1	0.1	0.1	0.1	0.1
Net change in investing activities	0.1	0.1	0.1	0.1	0.1
Financing Activities					
Proceeds from issuance of debt	0.1	0.1	0.1	0.1	0.1
Proceeds from sale of investments	0.1	0.1	0.1	0.1	0.1
Change in other assets and liabilities	0.1	0.1	0.1	0.1	0.1
Net change in financing activities	0.1	0.1	0.1	0.1	0.1
Net change in net assets	0.1	0.1	0.1	0.1	0.1
Net assets at beginning of year	0.1	0.1	0.1	0.1	0.1
Net assets at end of year	0.2	0.2	0.2	0.2	0.2

S a e e f Change i a Ne A e



Statement of Change in Net Assets

Year ended December 31, 2022 (continued)	Cash Flows from Operations C 3	Cash Flows from Investments C 2	Cash Flows from Financing C 3	Cash Flows from Other C 2	Cash Flows from Other C 3
Operating Activities					
Net income	\$ 1.1	\$ (1.1)	\$ (1.1)	\$ (1.1)	\$ (1.1)
Depreciation and amortization	(1.1)			(1.1)	
Provision for doubtful accounts					
Change in accounts receivable	(1.1)	(1.1)	(1.1)	(1.1)	(1.1)
Change in accounts payable	(1.1)	(1.1)	(1.1)	(1.1)	(1.1)
Change in other assets					
Change in other liabilities					
Change in net assets	\$ (1.1)	\$ (1.1)	\$ (1.1)	\$ (1.1)	\$ (1.1)
Investing Activities					
Proceeds from sale of investments	1.1	1.1	1.1	1.1	1.1
Proceeds from sale of other assets	1.1	1.1		(1.1)	(1.1)
Proceeds from sale of other liabilities	(1.1)	(1.1)	(1.1)	(1.1)	(1.1)
Change in other assets	(1.1)	(1.1)	(1.1)	(1.1)	(1.1)
Change in other liabilities	(1.1)	(1.1)	(1.1)	(1.1)	(1.1)
Change in net assets	\$ (1.1)	\$ (1.1)	\$ (1.1)	\$ (1.1)	\$ (1.1)
Financing Activities					
Proceeds from sale of investments		11.1			11.1
Proceeds from sale of other assets				1.1	1.1
Proceeds from sale of other liabilities	(1.1)	(1.1)	(1.1)	(1.1)	(1.1)
Change in net assets	11.1	11.1	11.1	11.1	11.1

Statement of Change in Net Assets

COPYL d

Year ended December 31, 2022 (continued)

[Redacted]

[Redacted]

[Redacted]

S a e e f C h a n g e i n A e

Statement of Change in Net Assets

Year ended December 31, 2022 (continued)	Cash Flows from Operations US\$ Millions	Cash Flows from Investing US\$ Millions	Cash Flows from Financing US\$ Millions	CS Reinvested US\$ Millions	CTIVP ACD/B US\$ Millions
Operating Activities					
Net income	\$ 1.0	\$ 0.0	\$ 0.0	\$ 0.0	\$ 0.0
Depreciation and amortization	(0.1)	(0.1)	(0.1)	(0.1)	(0.1)
Provision for doubtful accounts	(0.1)	(0.1)	(0.1)	(0.1)	(0.1)
Change in accounts receivable	(0.1)	(0.1)	(0.1)	(0.1)	(0.1)
Change in accounts payable	0.1	0.1	0.1	0.1	0.1
Change in other assets and liabilities	(0.1)	(0.1)	(0.1)	(0.1)	(0.1)
Net change in operating activities	0.5	0.5	0.5	0.5	0.5
Investing Activities					
Capital expenditures	(0.1)	(0.1)	(0.1)	(0.1)	(0.1)
Acquisition of property and equipment	(0.1)	(0.1)	(0.1)	(0.1)	(0.1)
Proceeds from sale of property and equipment	0.1	0.1	0.1	0.1	0.1
Change in other assets and liabilities	(0.1)	(0.1)	(0.1)	(0.1)	(0.1)
Net change in investing activities	(0.1)	(0.1)	(0.1)	(0.1)	(0.1)
Financing Activities					
Proceeds from issuance of common stock	0.1	0.1	0.1	0.1	0.1
Proceeds from sale of common stock	0.1	0.1	0.1	0.1	0.1
Change in other assets and liabilities	(0.1)	(0.1)	(0.1)	(0.1)	(0.1)
Net change in financing activities	0.1	0.1	0.1	0.1	0.1
Net change in cash and cash equivalents	0.5	0.5	0.5	0.5	0.5
Cash and cash equivalents at beginning of period	0.5	0.5	0.5	0.5	0.5
Cash and cash equivalents at end of period	1.0	1.0	1.0	1.0	1.0

Statement of Change in Net Assets

Year ended December 31, 2022 (continued)	CTIVP	CTIVP	CTIVP	CTIVP	CTIVP
	BRG I- P \$ c, C 2	BRG I- P \$ c, C 3	C S- R a E C 2	MFS Va, C 2	MS Ad/ C 2

0. a

Net Assets at beginning of year	\$.	\$.	\$. /	\$ (. /	\$ (.
Net Assets at end of year	(.	(/.	(.	.	(.

[Redacted]

[Redacted]

S a e e . f C h a n g e i n N e A e

CTIVP	CTIVP	CTIVP	CTIVP
P B 7	P B 7	T R P c	TCW C
C n G	C n G	W C a n V a	
C 1	C 2	C 2	

Y a d d D c b 31, 2022 (c 7 d)



S a e e f C h a n g e i n A e

[Redacted]

[Redacted]

[Redacted]

Statement of Change in Net Assets

Year ended December 31, 2022 (continued)	DWS				
	Actual, CIB	Estimated, ICG	Fiduciary, SC2	Fiduciary, SC2(2)	Fiduciary, SC2(2)
Operating					
Operating income	\$.	\$.	\$ (.)	\$.	\$.
Operating expenses	(.)	(.)	(.)	(.)	(.)
Net operating income	(.)	(.)	(.)	(.)	(.)
Net investment income	(.)	(.)	(.)	(.)	(.)
Capital Gains					
Capital gains	(.)	(.)	(.)	(.)	(.)
Capital losses	(.)	(.)	(.)	(.)	(.)
Net capital gains	(.)	(.)	(.)	(.)	(.)
Net realized gains	(.)	(.)	(.)	(.)	(.)
Net unrealized gains	(.)	(.)	(.)	(.)	(.)
Net change in net assets	\$ (.)	\$ (.)	\$ (.)	\$ (.)	\$ (.)
Accumulated					
Accumulated net assets	(.)	(.)	(.)	(.)	(.)
Accumulated net assets	(.)	(.)	(.)	(.)	(.)
Accumulated net assets	(.)	(.)	(.)	(.)	(.)

S a e e . f C h a n g e i n N e A e

Y a d d D c b 31, 2022 (c 7 d)

F d V I P	F d V I P	F d V I P	F d V I P
G & I c,	G & I c,	G Q ⁽¹⁾ ,	I - C a r A ⁽¹⁾ ,
S V C	S V C 2	S V C 2 ⁽²⁾	S V C 2

[Redacted]

[Redacted]

[Redacted]

S a e e f Change i s Ne A e

[Redacted]

[Redacted]

[Redacted]

Statement of Change in Net Assets

Year ended December 31, 2022 (continued)

I/V VI
 D M d Ca: G S II
 I/V VI
 D r D r d, S I
 I/V VI
 D r D r d, S II
 I/V VI
 EOVI - E, S II
 I/V VI
 G ba, S II

Operating

Revenue	\$ 111	\$ 111	\$ 111	\$ 111	\$ 111
Expenses	(111)	(111)	(111)	(111)	(111)
Net operating income	\$ 0	\$ 0	\$ 0	\$ 0	\$ 0

Capital

Contributions	111	111	111	111	111
Withdrawals	(111)	(111)	(111)	(111)	(111)
Net capital change	\$ 0	\$ 0	\$ 0	\$ 0	\$ 0

Accumulated Depreciation

Depreciation expense	111	111	111	111	111
Accumulated depreciation	(111)	(111)	(111)	(111)	(111)

Net change in net assets

Statement of Change in Net Assets

Year ended December 31, 2022 (continued)

	January 1, 2022	January 1, 2021	January 1, 2020	January 1, 2019
--	-----------------	-----------------	-----------------	-----------------

Operating assets

Operating liabilities

Operating assets

Operating liabilities

Statement of Change in Net Assets

Year ended December 31, 2022 (continued)	January 1, 2022	January 1, 2021	January 1, 2020	Laurens County, Georgia	Laurens County, Georgia
	Assets	Assets	Assets	Assets	Assets
Operating Assets	\$ (1,000)	\$ 1,000	\$ (1,000)	\$ (1,000)	\$ (1,000)
Investment Assets	1,000	1,000	1,000	1,000	1,000
Other Assets	1,000	1,000	1,000	1,000	1,000
Total Assets	\$ 1,000	\$ 1,000	\$ 1,000	\$ 1,000	\$ 1,000
Liabilities					
Accounts Payable					
Accrued Expenses					
Other Liabilities					
Total Liabilities	\$ 0	\$ 0	\$ 0	\$ 0	\$ 0
Net Assets	\$ 1,000	\$ 1,000	\$ 1,000	\$ 1,000	\$ 1,000

Statement of Change in Net Assets

Year ended December 31, 2022 (continued)	MFS Net Assets	MFS Reserve	MFS Unallocated	MS VIFD C II	MS VIFG ba Reserve C II
Operating					
Investment income	\$ (.)	\$.	\$.	\$ (.)	\$.
Interest income	(.)	(.)	(.)	(.)	(.)
Dividend income	(.)	(.)	(.)	(.)	(.)
Realized capital gains	(.)	(.)	(.)	(.)	(.)
Realized capital losses	(.)	(.)	(.)	(.)	(.)
Net operating income	\$ (.)	\$.	\$.	\$ (.)	\$.
Administrative					
Operating expenses	(.)	(.)	(.)	(.)	(.)
Investment expenses	(.)	(.)	(.)	(.)	(.)
Other expenses	(.)	(.)	(.)	(.)	(.)
Net administrative expenses	(.)	(.)	(.)	(.)	(.)
Net change in net assets	\$ (.)	\$.	\$.	\$ (.)	\$.
Accumulated					
Net change in net assets	(.)	(.)	(.)	(.)	(.)
Net change in net assets	(.)	(.)	(.)	(.)	(.)
Net change in net assets	(.)	(.)	(.)	(.)	(.)
Net change in net assets	(.)	(.)	(.)	(.)	(.)

S a e e f C h a n g e i n A e



Statement of Change in Net Assets

Year ended December 31, 2022 (continued)	PIMCO VIT Trust, Ltd. Advisor	PVT Global Health Care Fund	PVT Income Fund	PVT International Value Fund	PVT International Value Fund (2)
Operating					
Net investment income	\$ 1.0	\$ (1.0)	\$ 1.0	\$ (1.0)	\$ (1.0)
Dividend income	(1.0)		(1.0)	(1.0)	
Capital gains		1.0			
Realized gains	(1.0)	(1.0)	(1.0)	1.0	(1.0)
Realized losses	(1.0)	(1.0)	(1.0)		
Net change in operating assets	\$ (2.0)	\$ (2.0)	\$ (2.0)	\$ (2.0)	\$ (2.0)
Capital Gains					
Net capital gains		1.0	1.0		1.0
Net change in capital gains		1.0	1.0		1.0
Net change in operating assets		(1.0)	(1.0)		(1.0)
Net change in operating assets		(1.0)	(1.0)		(1.0)
Net change in operating assets		1.0	(1.0)		1.0
Net change in operating assets					
Net change in operating assets	\$ 1.0	\$ 1.0	\$ 1.0	\$ 1.0	\$ 1.0
Accumulated					
Net change in operating assets	1.0				
Net change in operating assets	1.0			1.0	1.0
Net change in operating assets	(1.0)	(1.0)	(1.0)		(1.0)
Net change in operating assets	1.0	1.0		1.0	1.0

Statement of Change in Net Assets

Year ended December 31, 2022 (continued)	Total Assets	Value of Investments	Value of Investments Sold	Value of Investments Purchased	Value of Investments Sold
	At Year End	At Year End	At Year End	At Year End	At Year End
Operating Activities					
Net income	\$ 100.00	\$ (100.00)	\$ (100.00)	\$ (100.00)	\$ (100.00)
Net change in cash	100.00	(100.00)	(100.00)	(100.00)	(100.00)
Investing Activities					
Net change in investments	(100.00)	100.00	100.00	100.00	100.00
Net change in cash	(100.00)	100.00	100.00	100.00	100.00
Financing Activities					
Net change in cash	100.00	(100.00)	(100.00)	(100.00)	(100.00)
Net change in cash	100.00	(100.00)	(100.00)	(100.00)	(100.00)
Accumulated Depreciation					
Net change in cash	100.00	(100.00)	(100.00)	(100.00)	(100.00)
Net change in cash	100.00	(100.00)	(100.00)	(100.00)	(100.00)

1. ORGANIZATION

RiverSource of New York Variable Annuity Account (the Account) was established under New York law as a segregated asset account of RiverSource Life Insurance Co. of New York (RiverSource Life of NY). The Account is registered as a unit investment trust under the Investment Company Act of 1940, as amended (the 1940 Act) and exists in accordance with the rules and regulations of the New York State Department of Financial Services.

The Account is used as a funding vehicle for individual variable annuity contracts issued by RiverSource Life of NY. The following is a list of each variable annuity product funded through the Account.

- RiverSource® Retirement Advisor Advantage Plus Variable Annuity (RAVA Advantage Plus)
- RiverSource® Retirement Advisor Select Plus Variable Annuity (RAVA Select Plus)
- RiverSource® Retirement Advisor 4 Advantage® Variable Annuity (RAVA 4 Advantage)
- RiverSource® Retirement Advisor 4 Select® Variable Annuity (RAVA 4 Select)
- RiverSource® Retirement Advisor 4 Access® Variable Annuity (RAVA 4 Access)
- RiverSource® RAVA 5 Advantage® Variable Annuity (RAVA 5 Advantage) (Offered for contract applications signed on or after April 30, 2012 but prior to April 29, 2013)
- RiverSource® RAVA 5 Select® Variable Annuity (RAVA 5 Select) (Offered for contract applications signed on or after April 30, 2012 but prior to April 29, 2013)
- RiverSource® RAVA 5 Access® Variable Annuity (RAVA 5 Access) (Offered for contract applications signed on or after April 30, 2012 but prior to April 29, 2013)
- RiverSource® RAVA 5 Advantage® Variable Annuity (RAVA 5 Advantage) (Offered for contract applications signed prior to April 30, 2012)
- RiverSource® RAVA 5 Select® Variable Annuity (RAVA 5 Select) (Offered for contract applications signed prior to April 30, 2012)
- RiverSource® RAVA 5 Access® Variable Annuity (RAVA 5 Access) (Offered for contract applications signed prior to April 30, 2012)
- RiverSource® RAVA 5 Advantage® Variable Annuity (RAVA 5 Advantage) (Offered for contract applications signed on or after April 29, 2013)
- RiverSource® RAVA 5 Select® Variable Annuity (RAVA 5 Select) (Offered for contract applications signed on or after April 29, 2013)
- RiverSource® RAVA 5 Access® Variable Annuity (RAVA 5 Access) (Offered for contract applications signed on or after April 29, 2013)
- RiverSource® RAVA 5 Advantage® Variable Annuity (RAVA 5 Advantage) (Offered for contract applications signed on or after April 29, 2019)
- RiverSource® RAVA 5 ChoiceSM Variable Annuity (RAVA 5 Choice)
- RiverSource® RAVA 5 Access® Variable Annuity (RAVA 5 Access) (Offered for contract applications signed on or after June 22, 2020)
- RiverSource® RAVA Apex NY Variable Annuity (RAVA Apex)
- RiverSource® RAVA Vista NY Variable Annuity (RAVA Vista)
- RiverSource® Flexible Portfolio Annuity (FPA)*
- RiverSource® Retirement Advisor Variable Annuity (RAVA)*
- RiverSource® Retirement Advisor Advantage Variable Annuity (RAVA Advantage)*
- RiverSource® Retirement Advisor Select Variable Annuity (RAVA Select)*

The Account is comprised of various divisions. Each division invests exclusively in shares of the following funds or portfolios (collectively, the Funds), which are registered under the 1940 Act as open-end management investment companies. The name of each Fund and the corresponding division name are provided below. Each division is comprised of subaccounts. Individual variable annuity accounts invest in subaccounts. For each division, the financial statements are comprised of a statement of assets and liabilities as of December 31, 2023, a related statement of operations for the year then ended and statements of changes in net assets for each of the two years in the period then ended, all presented to reflect a full twelve month period except as noted below.

Division	Fund

The assets of each division of the Account are not chargeable with liabilities arising out of the business conducted by any other segregated asset account or by RiverSource Life of NY.

RiverSource Life of NY serves as issuer of the contracts.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Investment Transactions

Investment transactions are accounted for on the date the shares are purchased and sold. Realized gains and losses on the sales of investments are computed using the average cost method. Income from dividends and gains from realized capital gain distributions are reinvested in additional shares of the Funds and are recorded as income by the divisions on the ex-dividend date. Unrealized appreciation or depreciation of investments in the accompanying financial statements represents the division's share of the Funds' undistributed net investment income, undistributed realized gain or loss and the unrealized appreciation or depreciation on their investment securities.

The assets of each division of the Account are not chargeable with liabilities arising out of the business conducted by any other segregated asset account or by RiverSource Life of NY.

RiverSource Life of NY serves as issuer of the contracts.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Investment Transactions

Investment transactions are accounted for on the date the shares are purchased and sold. Realized gains and losses on the sales of investments are computed using the average cost method. Income from dividends and gains from realized capital gain distributions are reinvested in additional shares of the Funds and are recorded as income by the divisions on the ex-dividend date. Unrealized appreciation or depreciation of investments in the accompanying financial statements represents the division's share of the Funds' undistributed net investment income, undistributed realized gain or loss and the unrealized appreciation or depreciation on their investment securities.

The Account categorizes its fair value measurements according to a three-level hierarchy. An investment's level within the fair value hierarchy is based on the lowest level of any input that is deemed significant to the fair value measurement. The three levels of the fair value hierarchy are defined as follows:

Level 1 – Unadjusted quoted prices for identical assets or liabilities in active markets that are accessible at the measurement date.

Level 2 – Prices or valuations based on observable inputs other than quoted prices in active markets for identical assets and liabilities.

Level 3 – Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.

The Funds in the Accounts have been measured at fair value using the net asset value per share (or its equivalent) as a practical expedient and are therefore not categorized in the fair value hierarchy. There were no transfers between levels in the period ended December 31, 2023.

Variable Payout

Net assets allocated to contracts in the payout period are periodically compared to a computation which uses the Annuity 2000 Basic Mortality Table and which assumes future mortality improvement. The assumed investment return is 3.5% or 5% based on the annuitant's election, or as regulated by the laws of the respective states. The mortality risk is fully borne by RiverSource Life of NY and may result in additional amounts being transferred into the variable annuity account by RiverSource Life of NY to cover greater longevity of annuitants than expected. Conversely, if amounts allocated exceed amounts required, transfers may be made to the insurance company.

Federal Income Tax

RiverSource Life of NY is taxed as a life insurance company. The Account is treated as part of RiverSource Life of NY for federal income tax purposes. Under existing federal income tax law, no income taxes are payable with respect to any investment income of the Account to the extent the earnings are credited under the contracts. Based on this, no charge is being made currently to the Account for federal income taxes. RiverSource Life of NY will review periodically the status of this policy. In the event of changes in the tax law, a charge may be made in future years for any federal income taxes that would be attributable to the contracts.

Subsequent Events

Management has evaluated Account related events and transactions that occurred through the date the financial statements were issued. Management noted there were no items requiring adjustments or additional disclosures in the Account's financial statements.

Use of Estimates

The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements. Actual results could differ from those estimates.

3. VARIABLE ACCOUNT EXPENSES

RiverSource Life of NY deducts a daily mortality and expense risk fee equal, on an annual basis, to the following percent of the average daily net assets of each subaccount.

Product	Mortality and Expense Risk Fee
Product 1	(d) % (d) % (c) ac (c) d)
Product 2	(d) % (d) % (c) ac (c) d)
Product 3	1 % (d) % (c) ac (c) d)
Product 4	(d) % (d) % (c) ac (c) d)
Product 5	(d) % (d) % (c) ac (c) d)
Product 6	(d) % (d) % (c) ac (c) d)

	A D c b 31				F a d d c b 31			
	U (000)	Acc 7 7	7 7	N a (000)	I c	E a	T a	(4)
C_VPH Y_d B_d, C 2		\$	\$	\$	%	%	%	%
		\$	\$	\$	%	%	(%)	(%)
		\$	\$	\$	%	%	%	%
		\$ /	\$ /	\$	%	%	%	%
		\$	\$	\$	/ %	/ %	%	/ %
C_VPH Y_d B_d, C 3		\$ /	\$	\$ /	%	%	%	%
	/	\$	\$	\$ /	/ %	%	(%)	(%)
		\$ /	\$	\$	%	%	%	%
		\$	\$	\$	%	%	%	%
		\$	\$ /	\$	%	%	/ %	%
C_VPI c O,,, C 2		\$	\$	\$	// %	%	/ %	%
	//	\$	\$	\$ /	%	%	(%)	(/ %)
		\$ /	\$	\$	/ %	/ %	/ %	%
		\$	\$	\$ /	%	/ %	/ %	/ %
	/	\$	\$	\$	/ %	/ %	/ %	%
C_VPI c O,,, C 3	//	\$	\$	\$	%	%	%	%
		\$	\$	\$	%	%	(%)	(%)
		\$	\$ /	\$	/ %	%	%	%
		\$	\$	\$	%	%	%	%
		\$	\$	\$	%	%	%	%
C_VPI B_d, C 2		\$ /	\$	\$	%	%	/ %	%
		\$	\$	\$	%	%	(/ %)	(/ %)
		\$	\$	\$	%	/ %	/ %	(%)
		\$	\$	\$	%	/ %	/ %	%
		\$	\$	\$	%	/ %	/ %	/ %
C_VPI B_d, C 3		\$	\$	\$	%	%	%	%
	//	\$	\$	\$	%	%	(%)	(/ %)
		\$ /	\$	\$ /	%	%	(%)	(%)
	/ /	\$ /	\$	\$	%	%	/ %	/ %
	/ /	\$	\$	\$	%	%	/ %	%
C_VPI Ca, G , C 2		\$	\$	\$ /		%	/ %	/ %
		\$ /	\$	\$ /		%	/ %	(%)
	//	\$	\$	\$		/ %	/ %	%
		\$ /	\$ //	\$		/ %	/ %	%
		\$	\$	\$		/ %	/ %	%
C_VPI Ca, G , C 3	/	\$	\$	\$		%	%	%
		\$	\$	\$		%	%	(/ %)
		\$	\$	\$		%	%	/ %
		\$	\$	\$ /		%	%	/ %
	/	\$	\$	\$		%	%	%
C_VPI Ca, I d , C 2		\$	\$	\$		%	%	/ %
	//	\$	\$	\$		%	%	(%)
		\$	\$	\$		%	%	(%)

	A D c b 31				F a d d c b 31			
	U (000)	Acc 7 7a	7 7a 7	N a (000)	I 7 c a (2)	E 7 a 7	T a 7	(4)
C_ YPS_ c M d Ca Va, C 2		\$ /	\$	\$ /		% / %	% / %	
		\$ /	\$	\$ /		% / %	(% ((%
		\$ /	\$	\$ /		/ % / %	/ %	%
		\$ /	\$	\$		/ % / %	%	%
	/	\$	\$ /	\$ / /		/ % / %	%	/ / %
C_ YPS_ c M d Ca Va, C 3		\$ /	\$	\$		%	%	/ % / %
		\$	\$	\$		%	%	(% (/ %
	/	\$	\$	\$		%	%	%
		\$	\$	\$ /		%	%	/ % / %
		\$ /	\$	\$		%	%	%
C_ YPS_ c S Ca Va, C 2		\$ /	\$	\$		% / %	%	/ %
		\$	\$	\$		% / %	(% ((/ %
		\$	\$	\$		/ % / %	%	/ %
		\$	\$	\$		/ % / %	/ %	%
		\$	\$	\$		/ % / %	%	%
C_ YPS_ c S Ca Va, C 3		\$ /	\$	\$		%	%	%
		\$	\$	\$		%	%	(% (
		\$	\$	\$ /		%	%	/ % / %
		\$	\$	\$		%	%	/ % / %
		\$	\$	\$		%	%	% / %
C_ YPS_ Gh T c, C 2		\$	\$	\$		%	%	%
		\$ /	\$ /	\$ /		%	%	(% (
C_ YPS_ Ca Va, C 2		\$	\$ /	\$		%	%	/ % / %
		\$	\$ /	\$		%	%	(% (
C_ YPS_ a i c l c, C 2		\$	\$ /	\$		%	% / %	/ %
		\$	\$	\$		%	% / %	(% (
	/	\$	\$	\$		%	/ % / %	%
		\$	\$	\$		%	/ % / %	%
		\$	\$	\$		%	/ % / %	% / %
C_ YP US G v M, C 2		\$ /	\$	\$		%	% / %	%
		\$	\$ /	\$		%	% / %	(/ % (/ %
		\$	\$	\$ /		%	/ % / %	(% (
	/	\$	\$	\$		%	/ % / %	%
	/	\$	\$	\$		%	/ % / %	%
C_ YP US G v M, C 3		\$	\$	\$		%	%	%
	/	\$ /	\$	\$ /		/ %	%	(% (
		\$	\$ /	\$		%	%	(% (
		\$	\$	\$		%	%	/ %
		\$	\$	\$		%	%	% / %
CSC_ d R, C 1		\$	\$	\$		%	%	(% (
	/	\$	\$	\$ /		%	%	%
		\$	\$	\$		/ %	%	%
		\$	\$	\$		%	%	(% (
		\$	\$	\$		/ %	%	%

	A D c b 31			F a d d c b 31				
	U (000)	Acc 7 7	7 7	N a (000)	I c	E a	T a 7	(4)
CTIVP AC D / B d, C 2		\$ /	\$	\$ /	%	% / %	%	%
		\$ /	\$	\$	%	% / %	(%)	(%)
	//	\$	\$	\$	%	/ % / %	(%)	(%)
	/	\$	\$	\$	/ %	/ % / %	%	%
		\$	\$	\$	/ %	/ % / %	/ %	%
CTIVP BR G I - P \$ c, C 2		\$	\$	\$	/ %	% / %	%	%
		\$ /	\$	\$	/ %	% / %	(%)	(%)
	/	\$	\$	\$	%	/ % / %	%	%
		\$	\$	\$	%	/ % / %	/ %	%
		\$	\$	\$ /	%	/ % / %	%	%
CTIVP BR G I - P \$ c, C 3		\$	\$	\$	// %	%	%	%
	/	\$	\$	\$	%	%	(/ %)	(/ %)
	/	\$ /	\$	\$	/ %	%	%	%
		\$ /	\$	\$	%	%	/ %	%
	/	\$	\$	\$	%	%	%	%
CTIVP C S a R a E c 2		\$	\$	\$	/ %	% / %	/ %	%
		\$ /	\$	\$	%	% / %	(%)	(%)
		\$	\$	\$	%	/ % / %	%	/ %
		\$ /	\$	\$ /	%	/ % / %	(%)	(%)
		\$	\$	\$	%	/ % / %	%	/ %
CTIVP MFS Va, C 2	/	\$	\$	\$		% / %	/ %	/ %
		\$	\$	\$		% / %	(%)	(/ %)
		\$	\$	\$ /		/ % / %	%	/ %
		\$	\$ /	\$		/ % / %	%	%
		\$ /	\$	\$		/ % / %	/ %	%
CTIVP MS Adr, C 2		\$	\$	\$		% / %	%	/ %
		\$ /	\$ /	\$		% / %	(%)	(%)
		\$	\$	\$ /		/ % / %	(%)	(%)
		\$	\$	\$		/ % / %	%	/ %
	/	\$	\$	\$		/ % / %	/ %	%
CTIVP P B 7 C G, C 1		\$	\$	\$		%	%	/ %
		\$ /	\$ /	\$		%	%	(/ %)
	/	\$	\$	\$ /		%	%	/ %
		\$	\$	\$		%	%	%
		\$ /	\$	\$		%	%	/ %
CTIVP P B 7 C G, C 2		\$	\$	\$		% / %	/ %	%
		\$	\$	\$		% / %	(%)	(%)
		\$	\$ /	\$ /		/ % / %	/ %	%
		\$	\$	\$		/ % / %	%	%
		\$	\$	\$ /		/ % / %	%	%
CTIVP TR P c Ca Va, C 2		\$	\$	\$		% / %	/ %	/ %
		\$	\$ /	\$		% / %	(%)	(%)
	/	\$	\$	\$		/ % / %	%	%
	/	\$	\$	\$		/ % / %	%	%
		\$ /	\$	\$		/ % / %	%	%

	A D c b 31			F a d d c b 31				
	U (000)	Acc 7 7	7 7	N a (000)	I c	E a	T a 7	(4)
F d V I P E M S C 2		\$	\$	\$	%	%	%	/ %
		\$	\$	\$	%	%	%	(%)
F d V I P E S C 2		\$	\$	\$	%	%	%	%
	/	\$	\$	\$	%	%	%	%
F d V I P G & I c, S C		\$ /	\$	\$ /	%	%	%	%
		\$	\$	\$	%	%	%	(%)
		\$	\$	\$	%	%	%	/ %
		\$ /	\$	\$ /	%	%	%	%
		\$	\$	\$	%	%	%	/ %
F d V I P G & I c, S C 2		\$	\$	\$	%	%	%	%
		\$	\$	\$	/ %	%	%	(%)
	/	\$ //	\$	\$	%	%	%	%
		\$	\$	\$	%	%	%	%
	/	\$	\$	\$	%	%	%	/ %
F d V I P G Q u i, S C 2		\$	\$	\$ /		%	%	%
		\$ /	\$ /	\$		%	%	(%)
F d V I P I - C a i A n n, S C 2		\$	\$	\$	%	%	%	%
		\$	\$	\$	%	%	%	(%)
F d V I P I v S, S C 2		\$	\$	\$	%	%	%	/ %
		\$	\$	\$	%	%	%	(%)
F d V I P M d C a i, S C		\$	\$	\$	%	%	%	%
	/	\$	\$	\$	/ %	%	%	(%)
		\$	\$	\$	%	%	%	%
		\$	\$	\$	%	%	%	%
		\$	\$	\$	/ %	%	%	/ %
F d V I P M d C a i, S C 2		\$	\$	\$	%	%	/ %	%
		\$	\$	\$ /	%	%	/ %	(%)
		\$ /	\$	\$ /	%	%	/ %	%
	/	\$ //	\$ /	\$	%	%	/ %	%
	/	\$	\$	\$	/ %	%	/ %	%
F d V I P O r S C		\$	\$	\$	%	%	%	%
		\$ /	\$	\$ /	%	%	%	(%)
		\$	\$	\$	%	%	%	/ %
		\$	\$	\$	%	%	%	%
	/	\$	\$	\$ / (%				

	A D c b 31			F a d d c b 31				
	U (000)	Acc 7 7	7 7	N a (000)	I c	E a	T a 7	(4)
GS VIT S Ca E J	\$	\$	\$		%	%	/ %	/ %
	\$ /	\$	\$		%	%	(/ %)	(%)
	\$	\$	\$ /		/ %	%	/ %	%
	\$	\$	\$		%	%	%	%
	\$ /	\$	\$ /		%	%	%	%
GS VIT S Ca E J S V	\$	\$	\$		/ %	%	/ %	%
	\$	\$	\$		%	%	(%)	(%)
GS VIT U.S. E J	\$	\$	\$		/ %	%	%	%
	\$	\$ /	\$		/ %	%	(/ %)	(/ %)
	\$	\$	\$ /		/ %	%	/ %	%
	\$	\$ /	\$		/ %	%	%	/ %
	\$	\$	\$ /		%	%	%	%
I V I A Fa S I	\$ /	\$	\$			%	/ %	%
	\$	\$	\$			%	(%)	(%)
	\$	\$ //	\$			%	%	/ %
	\$	\$	\$		/ %	%	%	%
	\$	\$ /	\$ /			%	%	%
I V I A Fa S II	\$	\$	\$ /			%	/ %	/ %
	\$	\$	\$			%	(%)	(%)
	\$	\$	\$			%	%	%
	\$	\$ /	\$			%	%	%
	\$	\$	\$			%	/ %	%
I V I Ba R A c S II	\$	\$ /	\$			%	/ %	%
	\$ /	\$	\$		/ %	%	(/ %)	(/ %)
	\$	\$	\$		%	%	/ %	%
	\$ /	\$	\$		/ %	%	%	%
	\$	\$	\$			%	/ %	/ %
I V I C c S II	\$	\$	\$ /		%	%	/ %	%
	\$	\$	\$ /		%	%	%	/ %
	\$	\$	\$		%	%	%	%
	\$	\$	\$		%	%	(%)	(%)
	\$	\$	\$ /		%	%	%	%
I V I C E S I	\$	\$	\$		%	%	/ %	/ %
	\$	\$	\$ //		%	%	(%)	(%)
	//	\$	\$		%	%	%	%
	\$	\$	\$		%	%	%	%
	\$	\$	\$ /		%	%	%	%
I V I C P d S II	\$	\$ /	\$		%	%	%	%
	\$	\$	\$ /		/ %	%	(%)	(%)
I V I D Ca G S I	\$	\$	\$ /			%	%	/ %
	\$	\$	\$			%	(%)	(/ %)
	\$ /	\$	\$			%	/ %	/ %
	\$	\$	\$ //		%	%	/ %	%

	A D c b 31		N a	F a d d c b 31			
	U (000)	Acc 7 a 7 (000)		I r c a (2)	E u a	T a 7	(4)
I r V I D M d Ca r G , S II	\$	\$	\$	%	%	%	%
	\$	\$	\$ /	%	%	(%	(%
	\$ /	\$	\$	%	%	/ %	/ %
	\$	\$	\$	%	%	%	%
I r V I D r D r d , S I	\$ /	\$	\$	%	%	/ %	%
	\$	\$	\$	/ %	%	(%	(/ %
	\$ /	\$	\$	%	%	/ %	/ %
	\$	\$	\$	%	%	(%	(%
	\$	\$	\$	%	%	%	%
I r V I D r D r d , S II	\$	\$	\$ /	%	/ %	%	/ %
	\$	\$	\$	%	/ %	%	(%
/	\$	\$	\$	/ %	/ %	%	/ %
	\$	\$	\$	%	/ %	(/ %	(%
	\$	\$	\$	%	/ %	%	/ %

I r V I E Q V I - E S II

	A D c b 31				F a d d c b 31			
U (000)	Acc 7	7 a 7	7 a 7	N a (000)	I c a (2)	E a	T a	(4)
NB AMT I - E C S	\$	✓	\$	\$	%	%	%	%
	\$	✓	\$	\$ //	%	%	(%	(/ %
	\$	✓	\$	\$ /	%	%	%	%
	\$	✓	\$	\$	%	%	%	%
	\$	✓	\$	\$	%	%	1%	1%
NB AMT S E C S	\$ /	✓	\$	\$.	1%	%	1 %	%
	\$	✓	\$	\$	%	%	1 %	(% (%
	\$	✓	\$	\$.	%	1 %	1 %	%
	\$	✓	\$ /	\$	%	1 %	1 %	1 %
	\$	✓	\$ /	\$ //	%	1 %	1 %	%
NB AMT USE I d PWS a, C S	/	✓	\$	\$		%	1 %	%
	\$	✓	\$	\$		%	1 %	(% (%
	\$	✓	\$	\$	%	%	1 %	%
	\$	✓	\$	\$	11%	%	1 %	%
	\$	✓	\$	\$	%	%	1 %	%
PIMCO VIT A. A Adr C	\$	✓	\$ /	\$.	1 %	%	1 %	%
	\$	✓	\$	\$.	%	%	1 %	(% (%
	\$	✓	\$	\$.	11%	%	1 %	%
	\$ //	✓	\$	\$ /	1 %	%	1 %	%
	\$	✓	\$	\$.	%	%	1 %	%
PIMCO VIT G b Ma A c, Adr C	\$ /	✓	\$	\$ /	%	%	1 %	%
	\$	✓	\$	\$ /	1 %	%	1 %	(// % (// %
	\$	✓	\$	\$	%	%	1 %	1%
	\$	✓	\$	\$	1%	%	1 %	%

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and

BALANCE SHEETS

()

Dec 31,

2023

2022(1)

Assets

Current Assets		
Cash	\$ 100	\$ 100
Accounts Receivable	200	200
Inventory	300	300
Prepaid Expenses	100	100
Total Current Assets	\$ 700	\$ 700
Non-current Assets		
Property, Plant, and Equipment	100	100
Intangible Assets	100	100
Total Non-current Assets	200	200
Total Assets	\$ 900	\$ 900

Liabilities and Equity

Liabilities		
Current Liabilities		
Accounts Payable	\$ 200	\$ 200
Short-Term Debt	100	100
Total Current Liabilities	\$ 300	\$ 300
Non-current Liabilities		
Long-Term Debt	100	100
Total Non-current Liabilities	100	100
Total Liabilities	\$ 400	\$ 400
Equity		
Common Stock	100	100
Retained Earnings	400	400
Total Equity	\$ 500	\$ 500
Total Liabilities and Equity	\$ 900	\$ 900

()

STATEMENTS OF SHAREHOLDER'S EQUITY

(continued)

	Common Stock	Additional Paid-in Capital	Retained Earnings	Accumulated Other Comprehensive Income (Loss)	Total
Balance January 1, 2021	\$.	\$.	\$.	\$.	\$.
Net income			(.)	(.)	(.)
Net loss			(.)	(.)	(.)
Balance December 31, 2021 ⁽¹⁾			(.)	(.)	(.)
Net income			(.)	(.)	(.)
Net loss			(.)	(.)	(.)
Balance December 31, 2022 ⁽¹⁾			(.)	(.)	(.)
Net income			(.)	(.)	(.)
Net loss			(.)	(.)	(.)
Balance December 31, 2023	\$.	\$.	\$.	\$ (.)	\$.

(1) The balance at the beginning of the period is the ending balance of the prior period.

NOTES TO FINANCIAL STATEMENTS

1. NATURE OF BUSINESS AND BASIS OF PRESENTATION

RiverSource Life Insurance Co. of New York (the “Company”) is a stock life insurance company which is domiciled and holds a Certificate of Authority in the State of New York. The Company is a wholly owned subsidiary of RiverSource Life Insurance Company (“RiverSource Life”), which is domiciled in Minnesota. RiverSource Life is a wholly owned subsidiary of Ameriprise Financial, Inc. (“Ameriprise Financial”). The Company issues insurance and annuity products to customers in the State of New York.

The accompanying financial statements are prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) which vary in certain respects from reporting practices prescribed or permitted by the New York State Department of Financial Services (“New York Department”) (the Company’s primary regulator) as described in Note 15. Certain reclassifications of prior period amounts have been made to conform with the current presentation.

The Company evaluated events or transactions that occurred after the balance sheet date for potential recognition or disclosure through April 19, 2024, the date the financial statements were issued. No subsequent events or transactions requiring recognition or disclosure were identified.

The Company’s principal products are variable annuities, universal life (“UL”) insurance, including indexed universal life (“IUL”) and variable universal life (“VUL”) insurance, which are issued primarily to individuals. Waiver of premium and accidental death benefit riders are generally available with UL products, in addition to other benefit riders. Variable annuity contract purchasers can choose to add an optional guaranteed minimum death benefit (“GMDB”) rider to their contract.

The Company also offers payout annuities, term life insurance and disability income (“DI”) insurance.

The Company’s business is sold through the advisor network of Ameriprise Financial Services, LLC (“AFS”), a subsidiary of Ameriprise Financial. RiverSource Distributors, Inc., a subsidiary of Ameriprise Financial, serves as the principal underwriter and distributor of variable annuity and life insurance products issued by the Company.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The Company adopted Accounting Standards Update (“ASU”), *Accounting Standards Update (ASU) 2018-12, Financial Instruments—Credit Losses* (“ASU 2018-12”), effective January 1, 2023 with a transition date of January 1, 2021. The significant accounting policies for market risk benefits (“MRB”); deferred acquisition costs (“DAC”); deferred sales inducement costs (“DSIC”); reinsurance; policyholder account balances, future policy benefits and claims; and unearned revenue liability were added or updated as a result of adopting the new accounting standard. See Note 3 for additional information related

Mortgage loans are placed on nonaccrual status when either the collection of interest or principal has become 90 days past due or is otherwise considered doubtful of collection. When a loan is placed on nonaccrual status, unpaid accrued interest is reversed. Interest payments received on loans on nonaccrual status are generally applied to principal unless the remaining principal bala

for any contracts that include an additional liability for death or other insurance benefit. DAC related to life contingent payout annuities are grouped on a calendar-year annual basis for each legal entity for policies issued prior to 2021 and on a quarterly basis for each legal entity thereafter.

DAC related to annuity products (including variable deferred annuities, fixed deferred annuities, and life contingent payout annuities) are amortized based on initial premium. DAC related to life insurance products (including UL insurance, VUL insurance, IUL insurance, term life insurance, and whole life insurance) are amortized based on original specified amount (i.e., face amount). DAC related to DI insurance are amortized based on original monthly benefit.

The accounting contract term for annuity products (except for life contingent payout annuities) is the projected accumulation period. Life contingent payout annuities are amortized over the period which annuity payments are expected to be paid. The accounting contract term for life insurance products is the projected life of the contract. DI insurance is amortized over the projected life of the contract, including the claim paying period.

Deferred Sales Load Expense

Liabilities

The liabilities for traditional long-duration products include cash flows related to unpaid amounts on reported claims, estimates of benefits payable on claims incurred but not yet reported and estimates of benefits that will become payable on term life, whole life, DI, LTC, and life contingent payout annuity policies as claims are incurred in the future. The claim liability (also referred to as disabled life reserve) is presented together as one liability for future policy benefits.

A liability for future policy benefits, which is the present value of estimated future policy benefits to be paid to or on behalf of policyholders and certain related expenses less the present value of estimated future net premiums to be collected from policyholders, is accrued as premium revenue is recognized. Expected insurance benefits are accrued over the life of the contract

factors. The unearned revenue liability is recorded in Other liabilities and the amortization is recorded in Policy and contract charges.

Income Tax

ASU 2022-02, "Revisions to the Scope of Current Expected Credit Losses," and modifies the disclosure requirements for certain loan refinancing and restructuring by creditors when a borrower is experiencing financial difficulty. Rather than applying the recognition and measurement for TDRs, an entity must apply the loan refinancing and restructuring guidance to determine whether a modification results in a new loan or a continuation of an existing loan. The update also requires entities to disclose current-period gross write-offs by year of origination for financing receivables and net investments in leases within the scope of Subtopic 326-20, "Revisions to the Scope of Current Expected Credit Losses." The amendments are to be applied prospectively, but entities may apply a modified retrospective transition for changes to the recognition and measurement of TDRs. For entities that have adopted Topic 326, the amendments are effective for interim and annual periods beginning after December 15, 2022. The Company adopted the standard on January 1, 2023. The adoption of this update did not have an impact on the Company's financial condition and results of operations and modifications to disclosures are immaterial in the current period.

In August 2018, the FASB updated the accounting standard related to long-duration insurance contracts (ASU 2018-12). The guidance changes elements of the measurement models and disclosure requirements for an insurer's long-duration insurance contract benefits and acquisition costs by expanding the use of fair value accounting to certain contract benefits, requiring updates, if any, and at least annually, to assumptions used to measure liabilities for future policy benefits, changing the amortization pattern of deferred acquisition costs to a constant-level basis and removing certain shadow adjustments previously recorded in AOCI. Adoption of the accounting standard did not impact overall cash flows or regulatory capital requirements.

When the Company adopted the standard effective January 1, 2023 with a transition date of January 1, 2021 (the "transition date"), opening equity was adjusted for the adoption impacts to retained earnings and AOCI and prior periods presented (i.e. 2021 and 2022) were restated. The adoption impact as of January 1, 2021 was a reduction in total equity of \$76 million, of which \$23 million and \$53 million were reflected in retained earnings and AOCI, respectively.

The following table presents the effects of the adoption of the above new accounting standard to the Company's previously reported Balance Sheets:

Account	As Reported		As Reported		As Reported	
	Dec 31, 2022	Adjusted	Dec 31, 2022	Dec 31, 2021	Adjusted	Dec 31, 2021
Assets						
Investments	\$ 1,111	\$ 1,111	\$ 1,111	\$ 1,111	\$ 1,111	\$ 1,111
Other Assets	111	111	111	111	111	111
Liabilities						
Other Liabilities	111	111	111	111	111	111
Equity						
Retained Earnings	111	111	111	111	111	111
AOCI	(111)	(111)	(111)	(111)	(111)	(111)
Total Equity	\$ 111	\$ 111	\$ 111	\$ 111	\$ 111	\$ 111

4. REVENUE FROM CONTRACTS WITH CUSTOMERS

The following table presents disaggregated revenue from contracts with customers and a reconciliation to total revenues reported on the Statements of Income:

	Y a E d d D c b 31,		
	2023	2022	2021
Revenue from contracts with customers	\$.	\$.	\$.
Revenue from contracts with customers, net of discounts	/	/	/
Revenue from contracts with customers, net of discounts and other adjustments	.	.	/
Revenue from contracts with customers, net of discounts and other adjustments, net of impairment losses	.	.	/
Revenue from contracts with customers, net of discounts and other adjustments, net of impairment losses and other adjustments	/	/	/
Revenue from contracts with customers, net of discounts and other adjustments, net of impairment losses and other adjustments, net of other adjustments	/	.	/
T a v r c a c ' c z e s	.	.	/
	\$.	\$.	\$ /

The following table presents a rollforward of the allowance for credit losses on Available-for-Sale securities:

	C	y	a	D	b
(S	c	r		
			\$		
			(
			(

The following is a summary of Net investment income:

	Y a r e e d d c b 31,		
	2023	2022	2021
Net investment income	\$ 1,100	\$ 1,100	\$ 1,100
Interest income	1,100	1,100	1,100
Provision for credit losses	(1,100)	(1,100)	(1,100)
Net investment income	\$ 1,100	\$ 1,100	\$ 1,100

7. FINANCING RECEIVABLES

Financing receivables are comprised of mortgage loans and policy loans. See Note 2 for information regarding the Company’s accounting policies related to financing receivables and the allowance for credit losses.

Allowance for Credit Losses

The following table presents a rollforward of the allowance for credit losses:

	Month End
Beginning balance	\$ 1,100
Provision for credit losses	(1,100)
Net change	(1,100)
Ending balance	\$ 0

As of December 31, 2023 and 2022, accrued interest on mortgage loans was \$474 thousand and \$516 thousand, respectively, and is recorded in Accrued investment income and excluded from the amortized cost basis of mortgage loans.

Credit Quality Indicators

There were no nonperforming loans as of both December 31, 2023 and 2022. All loans were considered to be performing.

Management

The Company reviews the credit worthiness of the borrower and the performance of the underlying properties in order to determine the risk of loss on mortgage loans. Loan-to-value ratio is the primary credit quality indicator included in this review.

Based on this review, the mortgage loans are assigned an internal risk rating, which management updates when credit risk changes. There were no mortgage loans which management has assigned its highest risk rating as of both December 31, 2023 and 2022. Loans with the highest risk rating represent distressed loans which the Company has identified as impaired or expects to become delinquent or enter into foreclosure within the next six months. There were no mortgage loans past due as of both December 31, 2023 and 2022.

The tables below present the amortized cost basis of mortgage loans by year of origination and loan-to-value ratio:

	D c b 31, 2023						
	2023	2022	2021	2020	2019	P	T a
Less than 1%	\$ 1,100	\$ 1,100	\$ 1,100	\$ 1,100	\$ 1,100	\$ 1,100	\$ 1,100
1% - 10%							
10% - 20%							
20% - 30%							
30% - 40%							
40% - 50%							
Total	\$ 1,100	\$ 1,100	\$ 1,100	\$ 1,100	\$ 1,100	\$ 1,100	\$ 1,100

o. o.

8. DEFERRED ACQUISITION COSTS AND DEFERRED SALES INDUCEMENT COSTS

The following tables summarize the balances of and changes in DAC, including the January 1, 2021 adoption of ASU 2018-12.

	Variable Acquisition	Fixed Acquisition	Unamortized Liabilities	Variable Unamortized Liabilities	Identifiable Unamortized Liabilities
December 31, 2020	\$.	\$.	\$.	\$.	\$.
January 1, 2021	1		1		
Change	()	()	()	()	()
December 31, 2021	\$ 1	\$ 1	\$.	\$ 1	\$ 1

	Other Liabilities	Contingent Payment Accruals	Trade Warrant Liabilities	Debt Incurrence	Take Private
December 31, 2020	\$ ()	\$.	\$ /	\$.	\$.
January 1, 2021	1				

The following tables summarize the balances of and changes in DSIC, including the January 1, 2021 adoption of ASU 2018-12. DSIC are recorded in Other assets.

	Balance at December 31, 2020	Change during 2021	Balance at December 31, 2021
DSIC	\$.	\$ /	\$ /
DSIC	/ /	.	.
DSIC	(/	((/

	L C Pa A	T a d W L I a c	D a b I c I a c	L C T Ca I a c	T a A P d c
P Va 7 E v c d N P 7					
	\$	\$ /	\$.	\$.	\$.
		/	.	/	.
		.	((.
		/	(((
	\$	\$ /	\$. /	\$.	\$.
		/	.	.	.
	(/	(/	((
	\$	\$. /	\$.	\$.	\$.
		(/	(.	(
	\$	\$.	\$.	\$.	\$ // /
P Va 7 F 7 P c B					
	\$.	\$ /	\$. /	\$. /	\$.

	(/	/	(((
	\$.	\$. /	\$.	\$. /	\$.
	.	.	/	.	.
	(/	((/	(//
	\$.	\$. /	\$. /	\$.	\$. /
	(/	(.	.	(
	\$. /	\$.	\$.	\$ /	\$.
	\$	\$	\$	\$	\$
	\$. /	\$.	\$ //	\$. /	\$.
	.	.	.	/	.
	\$. /	\$.	\$ /	\$ /	\$ // /
	\$	\$. /	\$.	\$.	\$.
	\$	\$.	\$ /	\$.	\$ //
	\$.	\$.	\$.	\$.	\$.
	%	%	%	%	%
	%	%	%	%	%
			/		

The balances of and changes in additional liabilities related to insurance guarantees were as follows:

()	Y a r e e d d c b 31,			
	2023	2022	2021	2020
	U n e a r n e d R e v e n u e	V a r i a b l e U n e a r n e d R e v e n u e	O t h e r U n e a r n e d R e v e n u e	T a x A d v a n t a g e
U n e a r n e d R e v e n u e	\$ 1.1	\$.	\$.	\$.
V a r i a b l e U n e a r n e d R e v e n u e	. /	. /	. /	. /
O t h e r U n e a r n e d R e v e n u e	(. /)	(. /)	(. /)	(. /)
T a x A d v a n t a g e	(. /)	(. /)	(. /)	(. /)
	\$.	\$.	\$.	\$.
	%	%	%	%
	%	%	%	%
		/		

The amount of revenue and interest recognized in the Statements of Income was as follows:

()	Y a r e e d d c b 31,					
	2023		2022		2021	
	G r o s s P r o d u c t	I n t e r e s t	G r o s s P r o d u c t	I n t e r e s t	G r o s s P r o d u c t	I n t e r e s t
G r o s s P r o d u c t	\$ 1.1	\$.	\$.	\$. /	\$.	\$.
I n t e r e s t	. /	. /	. /	. /	. /	. /
	(. /)	(. /)	(. /)	(. /)	(. /)	(. /)
	\$.	\$.	\$.	\$.	\$.	\$. /

The following TDL summarizes The balances of and changes in unearned revenue, including The January 1, 2021 adoption of ASU 2018-12:

()	Y a r e e d d c b 31,			
	2023	2022	2021	2020
	U n e a r n e d R e v e n u e	V a r i a b l e U n e a r n e d R e v e n u e	I d e n t i f i e d U n e a r n e d R e v e n u e	T a x A d v a n t a g e
U n e a r n e d R e v e n u e	\$ 1.1	\$. /	\$.	\$.
V a r i a b l e U n e a r n e d R e v e n u e	. /	. /	. /	. /
I d e n t i f i e d U n e a r n e d R e v e n u e	(. /)	(. /)	(. /)	(. /)
T a x A d v a n t a g e	(. /)	(. /)	(. /)	(. /)
	\$.	\$.	\$.	\$.

11. SEPARATE ACCOUNT ASSETS AND LIABILITIES

The fair value of separate account assets is invested exclusively in mutual funds.

No gains or losses were recognized on assets transferred to separate accounts for the years ended December 31, 2023, 2022 and 2021.

The balances of and changes in separate account liabilities were as follows:

	Va A	ah L	Va U	ah L	T a
	\$. . .		\$. . .		\$. . .
	/ .		. /		/ .
	(.		(/ .		(.
	(/ .		(.		(/ .

December 31, 2022

	Fair Value	Value	Change	Significant Assumptions	Rate	Weighted Average
...	\$				%	%
...					%	%
...					%	%
...					%	%
...					%	%

Change Significant Assumptions:

During the years ended December 31, 2023 and 2022, the Company updated inputs and assumptions based on management's review of experience studies. These updates resulted in the following notable changes in the fair value estimates of market risk benefits calculations:

Year ended December 31, 2023

- Updates to utilization of guaranteed withdrawals assumptions resulted in a decrease to pre-tax income of \$1.5 million.
- Updates to surrender assumptions resulted in a decrease to pre-tax income of \$5.0 million.

Year ended December 31, 2022

- Updates to utilization of guaranteed withdrawals assumptions resulted in a decrease to pre-tax income of \$1.9 million.
- Updates to surrender assumptions resulted in a decrease to pre-tax income of \$10.1 million.
- Updates to mortality assumptions resulted in a decrease to pre-tax income of \$2.1 million.

Refer to the rollforward of market risk benefits for the impacts of changes to interest rate, equity market, volatility and nonperformance risk assumptions.

Impact of Fair Value Measurement

Significant increases (decreases) in utilization and volatility used in the fair value measurement of market risk benefits in isolation would have resulted in a significantly higher (lower) liability value.

Significant increases (decreases) in nonperformance risk and surrender assumptions used in the fair value measurement of market risk benefits in isolation would have resulted in a significantly lower (higher) liability value.

Significant increases (decreases) in mortality assumptions used in the fair value measurement of the death benefit portion of market risk benefits would have resulted in a significantly higher (lower) liability value.

Valuation Hierarchy

The Company categorizes its fair value measurements according to a three-level hierarchy. The hierarchy prioritizes the inputs used by the Company's valuation techniques. A level is assigned to each fair value measurement based on the lowest level input that is significant to the fair value measurement in its entirety.

The three levels of the fair value hierarchy are defined as follows:

- Level 1 Unadjusted quoted prices for identical assets or liabilities in active markets that are accessible at the measurement date.
- Level 2 Prices or valuations based on observable inputs other than quoted prices in active markets for identical assets and liabilities.
- Level 3 Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.

The following tables present the balances of assets and liabilities measured at fair value on a recurring basis:

Description	December 31, 2023			
	Level 1	Level 2	Level 3	Total
Assets				
U.S. Treasury Bills	\$ 100,000	\$ 0	\$ 0	\$ 100,000
U.S. Treasury Notes	0	100,000	0	100,000
U.S. Treasury Bonds	0	100,000	0	100,000
Corporate Bonds	0	100,000	0	100,000
Equity Securities	0	100,000	0	100,000
Real Estate	0	100,000	0	100,000
Other Assets	0	100,000	0	100,000
Liabilities				
Accounts Payable	0	0	0	0
Accounts Receivable	0	0	0	0
Other Liabilities	0	0	0	0

()

Lv_1 Lv_2 Lv_3 T a

Assets

	Lv_1	Lv_2	Lv_3	T a
Y Y A c X Y A T	\$	\$ / .	\$.	\$ / . /
A T Y A T		/ . /		/ . /
Y A Y A T		.		.
A T Y A T		.		.
A T Y A T		/		/
Y Y A c X Y A T		.		. /
Y A Y A T		.		.
N Y A T			/	. /
A T Y A T	/	/		.
A T Y A T	. /	. /		. /
Y A Y A T		.		.
A Y A T		.		.
A Y A T		.		. / (

	Ara. ah - Sa S c 7	P_c d Acc z Ba a c F 7 7 P_c B d Ca
(4 z d	C y a D b S c 7	IUL E b dd d D va /
x y x . y (x)	\$. /	\$(.
y (x)	((. (

Fair Value	Valuation Technique	Underlying Instrument	Risk	Weighted Average
\$.			%	%
\$. /				

Level 3 measurements not included in the tables above are obtained from non-binding broker quotes where unobservable inputs utilized in the fair value calculation are not reasonably available to the Company.

Uncertainty of Fair Value Measurement

Significant increases (decreases) in the yield/spread to U.S. Treasuries used in the fair value measurement of Level 3 corporate debt securities in isolation would have resulted in a significantly lower (higher) fair value measurement.

Significant increases (decreases) in nonperformance risk used in the fair value measurement of the IUL embedded derivatives in isolation would have resulted in a significantly lower (higher) fair value measurement.

Description of Fair Value

The Company uses valuation techniques consistent with the market and income approaches to measure the fair value of its assets and liabilities. The Company's market approach uses prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities. The Company's income approach uses valuation techniques to convert future projected cash flows to a single discounted present value amount. When applying either approach, the Company maximizes the use of observable inputs and minimizes the use of unobservable inputs.

The following is a description of the valuation techniques used to measure fair value and the general classification of these instruments pursuant to the fair value hierarchy.

Assets

Available for Sale

When available, the fair value of securities is based on quoted prices in active markets. If quoted prices are not available, fair values are obtained from third-party pricing services, non-binding broker quotes, or other model-based valuation techniques.

Level 1 securities primarily include U.S. Treasuries.

Level 4 (Yield TD.0037 T, ppro) valuation using broker quote description and bid prices are not available,

o C

t A

Policyholder account balances, future policy benefits and claims include fixed annuities in deferral status, non-life contingent fixed annuities in payout status and the fixed portion of a small number of variable annuity contracts classified as investment contracts. See Note 10 for additional information on these liabilities. Separate account liabilities are related to certain annuity products that are classified as investment contracts.

14. RELATED PARTY TRANSACTIONS

Revenues

See Note 4 for information about revenues from contracts with customers earned by the Company from related party transactions with affiliates.

Expenses

Charges by Ameriprise Financial and affiliated companies to the Company for use of joint facilities, technology support, marketing services and other services aggregated \$23.0 million, \$22.9 million and \$23.1 million for the years ended December 31, 2023, 2022 and 2021, respectively. Certain of these costs are included in DAC. Expenses allocated to the Company may not be reflective of expenses that would have been incurred by the Company on a stand-alone basis.

Interest

immediately preceding year end, or (ii) statutory net gain from operations for the immediately preceding calendar year, not to exceed 30% of statutory surplus as of the immediately preceding year end would require pre-notification to the New York Department and are subject to potential disapproval. Statutory net gain from operations was \$66.6 million, \$212.7 million and \$63.6 million for the years ended December 31, 2023, 2022 and 2021, respectively.

Comparisons of net income and shareholder's equity, as shown in the accompanying GAAP financial statements, to that determined using statutory accounting principles prescribed by the State of New York ("SAP") were as follows:

	Y a r s e n d e d D e c e m b e r 31,		
	2023	2022	2021
N e t I n c o m e			
GAAP	\$ 66.6	\$ 212.7	\$ 63.6
SAP	\$ 66.6	\$ 212.7	\$ 63.6

	D e c e m b e r 31,	
	2023	2022
S h a r e h o l d e r ' s E q u i t y		
GAAP	\$ 100.0	\$ 100.0
SAP	\$ 100.0	\$ 100.0

As of December 31, 2023 and 2022, bonds carried at \$220 thousand and \$215 thousand, respectively, were on deposit with the State of New York as required by law.

16. OFFSETTING ASSETS AND LIABILITIES

Certain financial instruments and derivative instruments are eligible for offset in the Balance Sheets. The Company's derivative instruments are subject to master netting and collateral arrangements and qualify for offset. A master netting arrangement with a counterparty creates a right of offset for amounts due to and from that same counterparty that is enforceable in the event of a default or bankruptcy. The Company's policy is to recognize amounts subject to master netting arrangements on a gross basis in the Balance Sheets.

The following tables present the gross and net information about the Company's assets subject to master netting arrangements:

The following tables present the gross and net information about the Company's liabilities subject to master netting arrangements:

	December 31, 2023						
	Assets	Other Assets	Other Liabilities	Financial Instruments	Cash	Securities	Net
Assets	\$ 1	\$	\$ 1	\$ (\$ (\$ (\$
Liabilities				(/
Total	\$ 1	\$	\$ 1	\$ (\$ (\$ (\$

	December 31, 2022						
	Assets	Other Assets	Other Liabilities	Financial Instruments	Cash	Securities	Net
Assets	\$ 1	\$	\$ 1	\$ (\$ (\$ (\$ /
Liabilities				(/
Total	\$ 1 /	\$	\$ 1 /	\$ (\$ (\$ (\$ /

In the tables above, the amount of assets or liabilities presented are offset first by financial instruments that have the right of offset under master netting or similar arrangements, then any remaining amount is reduced by the amount of cash and securities collateral. The actual collateral may be greater than amounts presented in the tables.

When the fair value of collateral accepted by the Company is less than the amount due to the Company, there is a risk of loss if the counterparty fails to perform or provide additional collateral. To mitigate this risk, the Company monitors collateral values regularly and requires additional collateral when necessary. When the value of collateral pledged by the Company declines, it may be required to post additional collateral.

Freestanding derivative instruments are reflected in Other assets and Other liabilities. Cash collateral pledged by the Company is reflected in Other assets and cash collateral accepted by the Company is reflected in Other liabilities. See Note 17 for additional disclosures related to the Company's derivative instruments.

17. DERIVATIVES AND HEDGING ACTIVITIES

Derivative instruments enable the Company to manage its exposure to various market risks. The value of such instruments is derived from an underlying variable or multiple variables, including equity and interest rate indices or prices. The Company primarily enters into derivative agreements for risk management purposes related to the Company's products and operations.

Certain of the Company's freestanding derivative instruments are subject to master netting arrangements. The Company's policy on the recognition of derivatives on the Balance Sheets is to not offset fair value amounts recognized for derivatives and

The deferred premium associated with certain of the above options is paid or received semi-annually over the life of the contract or at maturity. The following is a summary of the payments the Company is scheduled to make and receive for these options as of December 31, 2023:

	P Paid	P Received
/	\$	\$
/	\$	\$

Actual timing and payment amounts may differ due to future settlements, modifications or exercises of the contracts prior to the full premium being paid or received.

IUL products have returns tied to the performance of equity markets. As a result of fluctuations in equity markets, the obligation incurred by the Company related to IUL products will positively or negatively impact earnings over the life of these products. The equity component of IUL product obligations is considered an embedded derivative, which is bifurcated from the host contract for valuation purposes and reported on the Balance Sheets at fair value with changes in fair value reported in earnings. As a means of economically hedging its obligations under the provisions of this product, the Company enters into interest rate swaps, index options and futures contracts.

As discussed in Note 12, the Company issues variable annuity contracts that provide protection to contractholders from other-than-nominal capital market risk and expose the Company to other-than-nominal capital market risk. The Company economically hedges its obligations under these market risk benefits using options, swaptions, swaps and futures.

Credit Risk

Credit risk associated with the Company’s derivatives is the risk that a derivative counterparty will not perform in accordance with the terms of the applicable derivative contract. To mitigate such risk, the Company has established guidelines and oversight of credit risk through a comprehensive enterprise risk management program that includes members of senior management. Key components of this program are to require preapproval of counterparties and the use of master netting and collateral arrangements whenever practical. See Note 16 for additional information on the Company’s credit exposure related to derivative assets.

Certain of the Company’s derivative contracts contain provisions that adjust the level of collateral the Company is required to post based on the Company’s financial strength rating (or based on the debt rating of RiverSource Life’s parent, Ameriprise

19. INCOME TAXES

The components of income tax provision were as follows:

	Year ended December 31,		
	2023	2022	2021
Current	\$.	\$. /	\$.
Deferred	(.	(. /	(. /
Deductions	(.	(.	(.
	\$.	\$. /	\$.

The principal reasons that the aggregate income tax provision is different from that computed by using the U.S. statutory rate of 21% were as follows:

	Year ended December 31,		
	2023	2022	2021
	%	%	%
	(((
	(((
	%	%	/ %

The decrease in the Company's effective tax rate for the year ended December 31, 2022 compared to 2021 is primarily due to

0. C.

If recognized, approximately nil, \$218 thousand and \$218 thousand, net of federal tax benefits, of unrecognized tax benefits as of December 31, 2023, 2022 and 2021, respectively, would affect the effective tax rate.

The Company is not aware of any tax positions for which it is reasonably possible that the total amount of unrecognized tax benefits will significantly change in the next 12 months.

The Company recognizes interest and penalties related to unrecognized tax benefits as a component of the income tax provision. The Company recognized a net decrease of \$90 thousand for the year ended December 31, 2023, and a net increase of \$16 thousand and \$11 thousand in interest and penalties for the years ended December 31, 2022 and 2021, respectively. As of December 31, 2023 and 2022, the Company had a payable of nil and \$90 thousand related to accrued interest and penalties, respectively.

The Company files income tax returns as part of its inclusion in the consolidated federal income tax return of Ameriprise Financial in the U.S. federal jurisdiction and various state jurisdictions. As of December 31, 2023, the federal statutes of

G a a . F . A

The Company is required by law to be a member of the guaranty fund association in the State of New York. In the event of insolvency of one or more unaffiliated insurance companies, the Company could be adversely affected by the requirement to pay assessments to the guaranty fund association. The Company projects its cost of future guaranty fund assessments based on estimates of insurance company insolvencies provided by the National Organization of Life and Health Insurance Guaranty Associations and the amount of its premiums written relative to the industry-wide premium in the State of New York. The Company accrues the estimated cost of future guaranty fund assessments when it is considered probable that an assessment will be imposed, the event obligating the Company to pay the assessment has occurred and the amount of the assessment can be reasonably estimated.

As of both December 31, 2023 and 2022, the Company had no accrual established for estimated future guaranty fund assessments.

er

e 